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Abstract 
 
Parkinson’s disease is a widespread neurodegenerative disorder that affect 2% of 
the population above the age of 60. The hallmark of the pathology is the 
preferential degeneration of the dopaminergic neurons in the substantia nigra pars 
compacta of the midbrain, and the presence of proteinaceous inclusions called 
Lewy bodies in the surviving neurons (Braak 2004). In 10% of the cases, the 
disease is linked to mutation on several genes, among them α-synuclein, DJ-1, 
PARKIN, PINK1 and LRRK2, but in the vast majority of the cases the aetiology 
is still unknown (sporadic PD) (Gwinn-Hardy 2002). Post mortem studies and in 
vitro and in vivo PD model have revealed a possible interconnection between 
genetic and sporadic PD, which involves both mitochondrial dysfunction and 
oxidative stress as central players in the pathogenesis of the disease (Gilgun-
Sherki Y. et al. 2001, Mythri R. B. et al. 2011). Oxidative stress is a condition 
characterized by the inability of the cellular antioxidant defences to cope with the 
production of reactive oxygen species (ROS). This condition of unbalance 
between the production and the clearance of ROS causes irreversible damage to 
cellular components such as lipids, proteins and DNA, leading eventually to cell 
death (Lotharius et al. 2002). Among the enzymes implicated in the detoxification 
of ROS, are superoxide dismutases (SODs) that catalyze the dismutation of 
superoxide anion into molecular oxygen and hydrogen peroxide (Fridovich 1995). 
Since oxidative stress does not explain alone the selectivity death of dopaminergic 
neurons, the main working hypothesis is that dopamine itself could have a central 
role. Under physiological conditions, dopamine is synthesized in the cytosol and 
stored in synaptic vesicles by the action of Vesicular Monoamine Transporter 
(VMAT2) where it is stabilized by the low pH (Erickson, J. D 1992). If the 
amount of cytosolic DA exceeds the physiological concentration, DA is 
metabolized to the non-toxic metabolite 3,4-dihydroxyphenylacetic acid and 
hydrogen peroxide by the action of monoamine oxidase (MAO) and aldehyde 
dehydrogenase, or sequestered into lysosomes where it can auto-oxidize to form 
neuromelanin (NM). If not buffered by these pathways, cytosolic DA can be 
oxidized to DA-quinone (DAQs) (spontaneously or enzymatically), (Sulzer, D., 
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2000, Elsworth, J. D. 1997), a reaction that also leads to the formation of ROS. 
On these premise, we evaluated two line of research using a cellular model for PD 
(SH SY5Y cell line): one concerning about the effect of dopamine and its 
oxidized forms on cellular viability, the second one on the potential role of 
superoxide dismutases (1 and 2) over expression. 
From the use of different techniques we started to evaluate which kind of cell 
death pathway was activated by dopamine and DAQs. Looking for the presence of 
nuclear fragmentation, that is one of the later stages of apoptosis, we determined 
that both dopamine and DAQs induce cell death via apoptosis but the dopamine 
toxicity depends on its internalization by the action of the dopamine transporter 
(DAT), since the pre-treatment of cells with GBR 12909 (a DAT inhibitor) had a 
rescue effect. To confirm the apoptotic pathway we also evaluated another 
hallmark of apoptosis (one of the former stages of the apoptotic cascade): 
phosphatidil-serine externalization (PS) using ANNEXIN-V-FLUOS; a specific 
probe for PS. Using flow cytometry we confirm that both dopamine and DAQs 
induce cell death via apoptosis. Next we wanted to evaluate if dopamine and 
DAQs exert their toxicity from extracellular environment or they are required to 
enter in the cells. Treating cells with GBR12909, we demonstrate that dopamine 
needs to enter cells to exert its toxicity (since the treatment with the DAT inhibitor 
rescues cells from DA toxicity) while DAQs toxicity was not affected by this 
treatment leading to cell death. Since oxidative stress is one of the mechanisms 
that have been implicated in the pathogenesis of PD, and the chemistry of 
dopamine (auto-oxidation and enzyme-mediated oxidation) leads to the 
production of ROS, we evaluate the production of mitochondrial superoxide anion 
using a specific probe. The data demonstrate that only the auto oxidation of 
dopamine leads to the production of superoxide anion and dopamine is required to 
enter cell to exert its effect. To dissect more in depth the toxicity mechanism of 
both dopamine and DAQs, and since only cytosolic dopamine led to the 
production of mitochondrial superoxide anion, we asked if this two different 
oxidation processes activated different cell death pathways (the major are the 
mitochondrial one and the one mediated by death receptor) or not. From 
preliminary data we observed a marked difference in the activation of caspase 3 
and the subsequent cleavage and inactivation of Poly (ADP) ribose polymerase 
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(PARP) due to DAQs treatment convincing us to proceed in the investigation of 
the possible differences between this different oxidation processes. The second 
part of the work was focused on the role for superoxide dismutases 1 and 2 
against dopamine and DAQs cytotoxicity since previous data demonstrated a role 
in superoxide anion production and induction of cell death in the case of cytosolic 
dopamine. Over expression of both SOD1 and SOD2 revealed a protective effect 
against dopamine cytotoxity, while they were not able to counteract DAQs-
induced cell death. In the present work the main working hypothesis was that 
oxidative stress induced by dopamine and its oxidized forms accumulation could 
have a central role in the specific dopaminergic cell loss in Parkinson’s disease. 
The data obtained so far seems to highlights that dopamine and DAQs activates 
different apoptotic pathway that are superoxide anion-dependent for DA and 
superoxide anion-independent for DAQs. Since oxidative stress is considered one 
of the mechanism that interconnect genetic form and sporadic forms of the 
pathology and dopamine, in its oxidative chemistry, leads to the production of 
ROS, understanding which cell death pathways are activated and to which extent, 
is crucial to develop a therapy to counteract the start and the progression of the 
pathology. Data from the over expression of SODs demonstrate that compounds 
that counteract the production of superoxide anion (like SOD-mimetics that are 
currently used for other diseases) could have a protective role against the 
oxidative stress and the subsequent cell death condition induced by dopamine. 
Also compounds that block the activation of the apoptotic cascade induced by 
dopamine and DAQs could rescue cells from dying in this neurodegenerative 
disease.
Riassunto 
 
8 
 
Riassunto 
 
La malattia di Parkinson è una diffusa sindrome neurodegenerativa che affligge 
circa il 2% della popolazione oltre l’età dei 60 anni. La caratteristica principale 
della patologia è la preferenziale morte dei neuroni dopaminergici della substantia 
nigra pars compacta del mesencefalo, e la presenza di inclusioni proteinacee 
chiamate Lewy body nei neuroni sopravvissuti. Nel 10% dei casi, la malattia è 
collegata a mutazioni su diversi geni, tra i quali α-synucleina, DJ-1, PARKIN, 
PINK1 e LRRK2, ma nella maggior parte dei casi (Parkinson sporadico) (Gwinn-
Hardy 2002) l’eziologia è ancora sconosciuta. Da studi post mortem e da modelli 
in vitro e in vivo per il PD è stata rilevata una possibile connessione tra le forme 
genetiche e quelle sporadiche che implica sia la disfunzione mitocondriale e lo 
stress ossidativo come fattori centrali nella patogenesi della malattia (Gilgun-
Sherki Y. et al. 2001, Mythri R. B. et al. 2011). Lo stress ossidativo è una 
condizione in cui le capacità antiossidanti della cellula non sono in grado di 
sopperire alla produzione di specie reattive dell’ossigeno (ROS). Questa 
condizione di sbilanciamento tra la produzione e la detossificazione dei ROS 
causa danni irreversibili ai componenti cellulari come lipidi, proteine e DNA, 
portando alla morte cellulare (Lotharius et al. 2002). Tra gli enzimi coinvolti nella 
difesa antiossidante delle cellule, le superossido dismutasi giocano un ruolo 
fondamentale poiché catalizzano la dismutazione dell’anione superossido in 
ossigeno molecolare e perossido di idrogeno (Fridovich 1995). Poiché lo stress 
ossidativo non spiega da solo la selettiva morte dei neuroni dopaminerigici, 
l’ipotesi è che la dopamina stessa abbia un ruolo chiave. In condizioni 
fisiologiche, la dopamina viene metabolizzata nel citosol e stoccata all’interno 
delle vescicole sinaptiche grazie all’azione del trasportatore vescicolare delle 
monoamine 2 (VMAT2) dove è stabilizzata dal basso pH (Erickson, J. D 1992).
 
Se la concentrazione citosolica di dopamina supera quella fisiologica, essa viene 
metabolizzata ad acido 3,4-diidrofenilacetico e perossido di idrogeno grazie 
all’azione dell’enzima monoamina ossidasi (MAO) e aldeide deidrogenasi, o 
sequestrata nei lisosomi dove può auto ossidarsi a formare neuromelanina. Se non 
è metabolizzata in questi pathway, la dopamina può essere ossidata a dopamino-
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chinoni (DAQs) (spontaneamente o enzimaticamente) (Sulzer, D., 2000, 
Elsworth, J. D. 1997)
, 
una reazione che produce anche specie reattive 
dell’ossigeno (ROS). Con queste premesse, abbiamo valutato due linee di ricerca 
usando un modello in vitro per il PD (la linea cellulare SH SY5Y): la prima 
riguardante l’effetto della dopamina e le sue forme di ossidazione sulla vitalità 
cellulare, la seconda sul potenziale ruolo dell’over espressione delle superossido 
dismutasi (1 e 2). 
Utilizzando differenti tecniche abbiamo iniziato a valutare quale pathway di morte 
cellulare veniva attivato dalla dopamina e dalle sue forme ossidate. Andando a 
valutare la frammentazione nucleare, uno degli ultimi stadi dell’apoptosi, abbiamo 
determinato che sia la dopamina sia i chinoni inducono l’attivazione di questo 
processo di morte. Per confermare il processo apoptotico, abbiamo valutato un 
altro marker: l’esternalizzazione delle fosfatidil-serine (PS): uno dei primi stadi di 
attivazione del processo apoptotico. con l’utilizzo di ANNEXIN-V-FLUOS, una 
sonda specifica per le PS. Mediante la tecnica di citoflurimetria abbiamo 
confermato che sia la dopamina che i chinoni attivano l’apoptosi. 
Successivamente abbiamo voluto valutare se la dopamina e i chinoni avevano 
effetti tossici a livello extracellulare o necessitavano di entrare nelle cellule. Pre-
trattando le cellule con l’inibitore specifico del trasportatore della dopamina (GBR 
12909) abbiamo dimostrato che la tossicità della dopamina è dipendente dal suo 
trasporto all’interno della cellula (in quanto il trattamento con l’inibitore ha avuto 
un effetto protettivo per le cellule), mentre i chinoni non lo necessitano. Poichè lo 
stress ossidativo è stato proposto come possibile meccanismo implicato nella 
patogenesi della malattia, e la chimica ossidativa della dopamina (auto 
ossidazione e ossidazione mediata da enzimi) porta alla produzione di specie 
radicaliche, abbiamo valutato la produzione dell’anione superossido (la prima 
specie radicalica prodotta soprattutto a livello del mitocondrio) usando una sonda 
specifica. I dati dimostrano che solo il processo auto ossidativo della dopamina 
porta alla produzione di anione superossido e che questo processo è dipendente 
dall’internalizzazione della dopamina a livello del trasportatore. Per comprendere 
maggiormente il meccanismo alla base della tossicità del processo di ossidazione 
e ossidazione mediate da enzima della dopamina abbiamo valutato altri marker di 
apoptosi. Poiché dai dati precedenti è stato visto che solo la dopamina citosolica 
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era in grado di indurre la produzione dell’anione superossido a livello del 
mitocondrio, abbiamo voluto verificare se i due processi ossidativi della 
dopamina, attivassero differenti pathway apoptotici (i prevalenti comprendo la via 
mediata dai recettori di morte, l’altro quella mitocondriale). Dati preliminari 
dimostrano una marcata attivazione della caspasi 3 e la conseguente inattivazione 
della poli (ADP) ribosio polimerasi in conseguenza al trattamento con i chinoni 
suggerendoci di investigare maggiormente sulle possibili differenze tra i diversi 
processi ossidativi della dopamina. La seconda parte del progetto si è focalizzata 
sul possibile ruolo delle superossido dismutasi 1 e 2 contro la tossicità indotta 
dalla dopamina e dai suoi prodotti di ossidazione. L’over espressione sia della 
SOD1 che della SOD2 hanno rivelato un effetto protettivo contro la produzione di 
anione superossido indotto dalla dopamina, mentre non hanno presentato alcun 
effetto contro la tossicità indotta dai chinoni rimarcando il ruolo dell’anione 
superossido nella tossicità indotta dalla dopamina. Nel presente progetto di 
dottorato, abbiamo valutato l’ipotesi che lo stress ossidativo indotto dalla 
dopamina e dalle sue specie ossidate possa avere un ruolo chiave nella specifica 
degenerazione dei neuroni dopaminergici caratteristici della malattia di Parkinson. 
I dati ottenuti sembrano dare indicazioni sulla differente attivazione di pathway di 
morte cellulare indotta dalla dopamina e dalle sue forme ossidate con un 
differente ruolo nella produzione dell’anione superossido. Poichè lo stress 
ossidativo è considerate uno dei meccanismi che collegano il Parkinson sporadico 
a quello genetico e la dopamina, nella sua chimica ossidativa, porta alla 
produzione di specie radicaliche, riuscire a capire quale pathway di morte 
cellulare è attivato e in quale misura, è cruciale per lo sviluppo di terapie per 
impedire l’inizio e la progressione della malattia. I dati derivanti dall’over 
espressione delle superossido dismutasi dimostrano che composti che 
impediscono la formazione dell’anione superossido (come SOD-mimetici che 
sono attualmente usati per altre patologie) potrebbero avere un ruolo protettivo 
contro lo stress ossidativo e la conseguente morte cellulare indotta. Inoltre, anche 
composti in grado ci bloccare la cascata apoptotica indotta da dopamina e chinoni 
potrebbe proteggere dalla morte le cellule affette in questa malattia 
neurodegenerativa. 
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1. Introduction 
 
Parkinson’s disease is a widespread neurodegenerative disease that was first 
described by James Parkinson (1755-1824) in his monograph ―An Essay of the 
Shaking Palsy‖ (Parkinson 1817). 
The author described the pathology as an ―involuntary tremolous motion, with 
lessened muscular power, in parts not in action and even when supported; with a 
propensity to bend the trunk forwards, and to pass from a walking to a runnin 
pace: the senses and intellect being uninjured‖. (Parkinson 1817) 
Jean Martin Charcot, one of the most important neurologist, proposed to name the 
disease as Parkinson’s disease (Lees 2009). From its description, a great effort 
was put on understanding the starting point and the progression of the pathology, 
but nowadays the cause of the pathology is still an open field. 
 
1.1 Parkinson’s disease 
 
1.1.1 Clinical and pathological hallmarks 
 
Parkinson’s disease (PD) is a widespread progressive neurodegenerative disease 
and it is second only to Alzheimer’s disease with an increasing incidence 
associated with age with a peak above 60 years old. The onset of the disease is 
gradual and the pre-clinical manifestations go unnoticed until more than the 80% 
of the neurons are lost (Lees, 2009). The features of PD comprise tremor at rest, 
bradykinesia, rigidity, loss of postural reflexes, flexed posture, and the freezing 
phenomenon (Fahn, 2003). In addition to the motor symptoms, there are also non 
motor manifestations. These include bradyphrenia (slowness in mental function), 
decreased motivation and apathy, dementia, fatigue, depression, anxiety, sleep 
disturbances (fragmented sleep and REM sleep behavior disorder), constipation, 
bladder and other autonomic disturbances (sexual, gastrointestinal), and sensory 
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complaints. Dementia is associated with age, and has been reported to occur in 
over 70% of patients with PD eventually (Chaudhuri, 2006). The pathological 
hallmarks of the disease are the selectivity death of the dopaminergic neurons in 
the substantia nigra pars compacta (SNpc) of the midbrain and in some cases of 
the presence of citoplasmatic inclusions called Lewy bodies composed by 
insoluble aggregates mainly composed of α-synuclein and ubiquitin (Spillantini 
1997, Shults, 2006). 
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Fig. 1. Neuropathology of Parkinson’s Disease. (A) Schematic representation of the normal 
nigrostriatal pathway (in red). dopaminergic neurons project (thick solid red lines) to the basal 
ganglia and synapse in the striatum (i.e., putamen and caudate nucleus). The photograph 
demonstrates the normal pigmentation of the SNpc, produced by neuromelanin within the 
dopaminergic neurons. (B) Schematic representation of the diseased nigrostriatal pathway (in red). 
In Parkinson’s disease, the nigrostriatal pathway degenerates. There is a marked loss of 
dopaminergic neurons demonstrated by the massive depigmentation. (C) Immunohistochemical 
labeling of intraneuronal inclusions, termed Lewy bodies, in a SNpc dopaminergic neuron. On the 
left, immunostaining with an antibody against α-synuclein while on the right, immunostaining 
against ubiquitin. (Dauer and Przedborski, 2003) 
 
In Parkinson’s disease, apart from the dopaminergic neurons, other areas are 
affected; among them, noradrenergic neurons in the locus coeruleus and 
serotoninergic neurons in the dorsal raphe nucleus (Braak et al. 2004, Shen and 
Cookson 2004). 
 
1.1.2 Treatments 
 
Dopamine replacement therapy is the major medical approach in treating PD, and 
a variety of dopaminergic agents are available. These drugs are: dopamine 
agonists (such as ropinerole and pramipexole) activating pre- and post-synaptic 
dopamine receptors, MAO-B (selegiline) and COMT inhibitor to reduce the 
catabolism of dopamine. The main drug used to replenish the dopamine lost is L-
DOPA: the dopamine precursor, but its use after some years leads to the 
appearance of other motor dysfunction such as dyskinesia ( involuntary 
movements) or wearing-off (Schapira 2009).  
Other kind of treatments include brain surgery known as deep brain stimulation 
(DBS) that can be appropriate for patients with advanced disease and 
complications from medications (Fahn 2003) and physical therapy that include 
exercises to maintain the joints and muscles loose and to learn techniques of better 
gait and balance. 
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1.1.3 Neuronal circuits implicated: the basal ganglia 
 
The basal ganglia (or basal nuclei) are a group of nuclei of different origin in the 
brains of vertebrates that act as a cohesive functional unit. They are situated at the 
base of the forebrain and are strongly connected with the cerebral cortex, thalamus 
and other brain areas. The basal ganglia are associated with a variety of functions, 
including voluntary motor control, procedural learning relating to routine 
behaviors or "habits". (Stocco et al. 2010) The main components of the basal 
ganglia are the striatum (caudate nucleus and putamen), the globus pallidus 
(divided in internal and external segment), the substantia nigra, and the 
subthalamic nucleus (Fix et al. 2008).  
 
 
Fig. 2. Structures involved 
in the basal ganglia 
circuits. (Dale Purves 
2001) 
 
Glutaminergic neurons raising from the cerebral cortex projects to the spiny 
neuron of the striatum, which also receive projections from both the thalamus and 
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brain stem (dopaminerigc input from the midbrain and serotoninergic projections 
from the raphe nuclei). The striatum send its projections in the substantia nigra 
pars reticulate and to the globus pallidus (internal segment). Neurons of the 
substantia nigra pars reticulata inhibit the superior colliculus, while those of the 
internal segment of globus pallidus inhibit the anterior ventral nucleus and the 
lateral ventral nucleus (in the thalamus). The thalamus stimulates the motor cortex 
via glutamatergic projections. At rest, cortical neurons are inhibited while the 
neurons of the internal segment of globus pallidus and the susbtantia nigra pars 
reticulate are activated, inhibiting the thalamic neurons. On the other hand, when 
the cortex neurons are excited activating the striatum, they inhibit the downstream 
neurons, activating the thalamus leading to the activation of motor cortex neurons 
and facilitating movements (direct pathway). Another pathway, the indirect one, 
comprises spiny neurons of the striatum that projects first to the external segment 
of globus pallidus and subsequently to internal segment and to the subtalamic 
nucleus (GABAergic projections).  
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Fig. 3. The basal ganglia-thalamocortical circuit in normal conditions (left) and in 
parkinosn’s disease (right). Excitatory connections are represented in pink, while inhibitory in 
grey and black arrows. Under normal conditions the indirect and the direct pathway modulate the 
dopaminergic neurons of the substantia nigra pars compacta. In Parkinson’s disease is absent the 
modulation from the SNc and there’s an increase in the inhibition of the thalamus leading to a 
difficulty to start movements. Changes in activity are represented with changes in the darkness of 
arrows: lighter arrows indicates a decreased activity, while the darker an increased activity. (Eric 
Kandel 2000). 
 
The latter is connected to the internal segment of globus pallidus and to the 
substantia nigra pars reticulata via excitatory glutamatergic projections. Once the 
indirect pathway is activated by cortical projections, the external segment of 
globus pallidus is inhibited leading to the disinhibition  of subtalamic nucleus 
stimulating the internal segment of the globus pallidus. The result is the inhibition 
of thalamus leading to the inhibition of movement. The direct pathway provides a 
positive feedback while the indirect a negative feedback on the circuit between the 
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basal ganglia and the thalamus. Neurons of the substantia nigra pars compacta 
have a role both in the direct and indirect pathway leading to an excitatory effect 
and inhibitory effect on the direct and indirect pathway respectively.  These 
neurons present two different kinds of dopamine receptors: D1 type receptor in 
the direct and D2 type receptor in indirect pathway (Dale Purves, 2001, Eric 
Kandel 2000). Both type of receptors are coupled to G-proteins leading to the 
activation of adenylyl cyclase (D1) and its inhibition (D2) resulting in a different 
cellular response (Vallone et al. 2000). Dopaminergic input leads to the inhibition 
of the thalamocortical circuit facilitating the movement. The dopaminergic 
neurons degeneration that occur in Parkinson’s disease, leads to the increase of 
inhibition in the basal ganglia. The output activity of the nuclei is increased 
leading to an increased inhibition of the thalamus inhibiting the activation of 
cortical neurons. This finally results in impaired movements (Dale Purves 2001, 
Eric kandell 2000) 
 
1.2 Etiology of parkinson’s disease 
 
1.3 Genetics forms of PD 
 
Parkinson’s disease has been described as a multifactorial pathology and 
nowadays the etiology of the disease is still unknown. Genetic predisposition, 
environmental toxins, protein misfolding and aggregation, neuroinflammation, 
oxidative stress, mitochondrial and proteasomal dysfunction have been proposed 
as possible mechanisms with aging considered the major risk factor associated 
with the appearance of the pathology. About 5% of the cases are linked to 
mutation on several genes that are listed in the tab. 1. (for a review see Bekris et 
al. 2010) 
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Locus Gene Chromosome Inheritance Probable function 
PARK1/4 alfa-
synuclein 
4q21 AD Presynaptic protein. Lewy 
bodies 
PARK2 Parkin 6q25.2-27 AR Ubiquitin E3 ligase 
PARK3 Unknown 2p13 AD Unknown 
PARK4 Unknown 4p14 AD Unknown 
PARK5 UCHL-1 4p14 AD Ubiquitin C-terminal 
Hydrolase 
PARK6 PINK1 1p35-36 AR Mitochondrial kinase 
PARK7 DJ-1 1p36 AR Chaperone, antioxidant 
PARK8 LRRK2 12p11.2 AD Mixed lineage kinase 
PARK9 ATP13A2 1p36 AR Unknown 
PARK10 Unknown 1p32 AD Unknown 
PARK11 Unknown 2q36-37 AD  Unknown 
PARK12 Unknown Xq21-q25 Unknown Unknown 
PARK13 HTRA2 2p12 Unknown Mitochondrial serine 
protease 
AD: autosomal dominant, AR: autosomal recessive. 
Tab. 1. Gene associated with PD. (Farrer 2006, Yang 2009). 
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1.3.1 Genes associated with autosomal dominant PD 
 
α -Synuclein (PARK1/4) 
Alfa-synuclein was the first gene discovered and associated with autosomal 
dominant PD in its mutations A30P (Kruger 1998) E46K (Zarranz 2004) and 
A53T (Polymeropoulos 1997), duplication and triplication (Singleton 2003). 
The gene product is a small protein (14,5 KDa) of 140 amino acids, natively 
unfolded whose physiological function is still unknown. Alfa synuclein is one of 
the major components of Lewy bodies (Shults 2006) and its ability to form 
oligomeric species and fibrils seems to account for its toxicity at the cellular level 
(Auluck 2010, Goedert 2001, Lotharius and Brundin 2002). 
Leucine-rich repeat kinase 2 (PARK8) 
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common 
forms of inheritable Parkinson's disease and likely play a role in sporadic disease 
as well. LRRK2 is a large multidomain protein with several physiological roles. 
The first mutation associated with the pathology was reported in 2002 (Funayama 
2002), but later on other mutations were associated with the onset of the disease. 
The disease appears to be dominant with an incomplete penetrance and Lewy 
bodies are not always present (Latourelle 2008). The phenotype of LRRK2 
mutation is referred to be pleomorphic since this protein is implicated in multiple 
signaling pathways (Zimprich 2004) 
 
1.3.2 Genes associated with autosomal recessive PD 
 
PARKIN (PARK2) 
Mutations in Parkin, an E3 ubiquitin ligase, cause a recessive, early-onset, slowly 
progressive parkinsonism accounting for the majority of early-onset familial PD. 
More than 100 distinct mutations have been identified for this gene. In one study 
of patients with onset of Parkinson disease prior to age 40 (10% of all PD 
patients), 18% had Parkin mutations, with 5% homozygous mutations.(Poorkaj 
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2004).  Parkin catalyzes the transfer of ubiquitin to target proteins to either mark 
them for degradation by the ubiquitin–proteasome system or for non-degradative 
signaling purposes. Recently, parkin has been implicated also in mitochondrial 
maintenance (Abou-Sleiman et al., 2006) 
 
PTEN-induced putative kinase 1 (PINK1)  
PTEN-induced putative kinase 1 (PINK1) is a mitochondrial serine/threonine-
protein kinase encoded by the PINK1 gene. Mutations in this gene are the second 
most common cause of autosomal recessive early-onset familial PD with most of 
the mutations affecting the kinase activity of the protein (Kawajiri et al. 2011, 
Harowitz and Greenamyre 2010, Thomas and Cookson 2009). Loss of PINK1 
function leads to a less protective effect of this protein on mitochondria 
maintenance and function against oxidative stress. (Akundi et al. 2011, Diedrich 
et al. 2011, Moore et al. 2005) 
 
DJ-1 
 
DJ-1 has an unknown function (Abou-Sleiman et al., 2003; Bonifati et al., 2003) 
and it has been linked to a rare, recessive form of parkinsonism called PARK7. 
(Bonifati et al. 2003). The exact function of DJ-1 is unknown, and it was first 
identified as a human oncogene (Nagakubo et al., 1997). Further studies 
demonstrated tha DJ-1 becomes more acidic in response to oxidative stressors, 
such as hydrogen peroxide or paraquat (Mitsumoto and Nakagawa, 2001; 
Mitsumoto et al., 2001). This suggests that DJ-1 might function in the oxidative 
stress response.  
 
Other genes and loci associated with PD 
 
Besides the gene listed above, there are several other gene and genetic loci that 
have been identified, but it is still object of  debate if there is an effective 
connection to PD. These genes are: ubiquitin carboxy-terminal hydroxylase 
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(UCHL-1) (PARK5), ATP132A2 (PARK9), Omi/HtrA2 (PARK13). UCHL-1 is a 
protein involved in the ubiquitin-proteasome system and is implicated in the 
hydrolysis of polymeric ubiquitin chains. Its presence in Lewy bodies is still 
controversial as well as the link between its mutation I93M and the polymorphism 
S18Y (Leroy et al. 1998, Lincoln et al. 1999, Hutter et al. 2008, Ragland et al. 
2009. ATP13A2 is a lysosomal membrane protein that belongs to the P5 
subfamily of P-type transport ATPases, a transporter family of 5 proteins 
(ATP13A1–5) with unknown substrates (Schultheis et al., 2004). ATP13A2 was 
found mutated in several cases of early onset PD (Di Fonzo et al., 2007; Santoro 
et al., 2011). Several studies linked this protein to the network of alfa-synuclein 
and in the regulation of mitochondria (Gitler et al., 2009, Gusdon et al., 2012, 
Grunewald et al., 2012). Omi/HtrA2 is a mitochondrial serine-protease that was 
also found in Lewy bodies. The G399S mutation and the A141S polymorphism 
were identified to correlate with PD (Strauss et al. 2005) but another study 
performed on a larger population did not confirm these data (Ross et al. 2008). All 
these genes and additional genetic loci are still on validation. 
 
1.4 Sporadic Parkinson’s disease 
 
1.4.1 Neuroinflammation 
 
Idiopathic Parkinson's disease (PD) represents a complex interaction between the 
vulnerability of the nigrostriatal dopaminergic system, a possible genetic 
predisposition, and exposure to environmental toxins including inflammation 
triggers. Mc Geer and collaborators, in 1990s, first proposed the involvement of 
neuroinflammation in the pathogenesis of PD, since they found activated 
microglia cells in the substantia nigra of PD patients. (Mc Geer et al. 1988). Other 
evidence, now suggest that chronic neuroinflammation is tightly associated with 
the pathophysiology of PD. Activation of microglia and increased levels of pro-
inflammatory mediators and reactive oxygen species has been found in post-
mortem analysis of the substantia nigra of PD patients and in animal models 
of PD. It has been suggest that there’s a vicious cycle between ROS production 
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and pro-inflammatory marker leading to the aggravation and progression of the 
pathology (Collinsa M. 2012, Glass et al. 2010). 
 
Fig. 4. Proposed mechanism of the involvement of inflammation in PD. (Glass et al. 2010) 
 
1.4.2 Proteasome dysfunction and protein aggregation  
 
The ubiquitin-proteasome system (UPS) is essential for the non-lysosomal 
degradation and clearance of dysfunctioning proteins (Sherman et al. 2001). This 
is mediated by a series of reactions mediated by different enzyme that identify 
abnormal proteins for degradation with a multiple ubiquitination tail. Ubiquitin is 
a key protein for the poly-ubiquitination of this kind of proteins, and it is 
generated by a ubiquitin-activating enzyme (E1), subsequently is transferred to 
ubiquitin-conjugating enzyme (E2) and ligated to lysine residues of the protein 
substrates in a reaction catalyzed by different ubiquitin protein ligase (E3). The 
complex formed is recognized and degraded by the 26S proteasome (DeMartino 
1999). In sporadic PD brains, a decreased activity of the ubiquitin-proteasome 
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system (UPS) was found and this was linked to the abnormal accumulation of 
misfolded proteins (Xie 2010). 
The first indication that a failure of the UPS could be a mechanism involved in the 
pathogenesis of PD, was suggested form the observation of the presence of Lewy 
bodies (Forno et al. 1996, Pollanen et al. 1993) and numerous group suggest that 
this inclusions were formed to prevent the possible cytotoxicity of poorly-
degraded proteins but this theme is still object of debate (Robinson 2008, Dawson 
et al. 2003, Shin et al. 2009). Another reason that reinforced the involvement of 
the proteasome system dysfunction in PD was linked to the discovery of  
mutations in the UCHL-1 and Parkin genes. Both proteins are involved in the UPS 
machinery with the first responsible for the recovery of free ubiquitin protein, and 
the latter for its ubiquitn-ligase activity. A loss of function in these proteins could 
account for the accumulation of poorly degraded proteins.  
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Fig. 5. A toxic or damaged protein can be detoxified via at least two pathways. The first 
involves the ubiquitin-proteasomal pathway (UPP) where the protein is tagged for degradation by 
the proteasome. If the toxic or damaged protein exceeds the capacity of the proteasome the 
ubiquitinated protein might serve as a nucleation center for aggregates and inclusion bodies. 
Aggresomes might be intermediates in the formation of inclusion bodies. Inclusion bodies and the 
UPP appear to work in a coordinated fashion to protect the cell from toxic or damaged proteins. 
The capacity of both of these systems might be overwhelmed, leading to further compromise in a 
feed-forward pathway that ultimately results in the demise of the neuron (Chung et al. 2001). 
 
1.4.3 Oxidative stress 
 
Oxidative stress is a condition in which the antioxidant defenses of the cells are 
not able to counteract the production of reactive oxygen and nitrogen species 
(ROS/RNS). The brain is more susceptible to oxidative stress for different 
reasons: a high consumption of molecular oxygen, high content of proteins and 
lipids that can be oxidized and low level of antioxidant molecules (Floyd 1999; 
Poon et al. 2004).  Numerous studies have confirmed increased levels of several 
markers of oxidative damage in the SN of PD patients: DNA damage, lipid 
peroxidation, protein oxidation, less glutathione in its reduced form, and increased 
iron deposition (Jenner and Olanow 1996). The role of oxidative stress is still 
object of debate:  is it a causative factor or simply a downstream consequence? 
(Andersen 2004). Oxidative stress can result from defects in several systems, such 
as mitochondrial dysfunction, increased calcium levels, neurotoxins and 
inflammatory responses and low antioxidant capacity. Moreover one potential 
source of ROS is dopamine (DA) itself that could provide the rational for the 
selectivity death of dopaminergic neurons (Graham et al. 1998). 
Overall, it appears that oxidative (and nitrative) stress can be linked both to 
sporadic and familial PD suggesting a prominent role in initiating and amplifying 
effect on pathways that favor cell death in this neurodegenerative disorder. 
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Cellular antioxidant defenses 
Oxidative stress is a condition where the over production of reactive oxygen a 
nitrogen species overwhelm the antioxidant capacity of a cell. Cellular levels of 
ROS are controlled by antioxidant enzymes and antioxidants small-molecules. 
 
Enzymatic antioxidants 
Superoxide Dismutase  
As major antioxidant enzymes, superoxide dismutases (SODs), play a crucial role 
in scavenging O2•−. The superoxide dismutase family is responsible in the 
dismutation of superoxide anion radicals into molecular oxygen and hydrogen 
peroxide. Three distinct isoforms of SOD have been identified and characterized 
in mammals: mostly cytosolic copper-zinc superoxide dismutase (SOD1), 
mitochondrial manganese superoxide dismutase (SOD2) and extracellular 
superoxide dismutase (SOD3). These isoforms of SOD exhibit similar functions, 
but requires different co-factor and exhibit different cellular localization. (for a 
review see Abreu et al. 2010). 
Glutathione Peroxidases  
Glutathione peroxidases are a family of isozymes that catalyze the reduction of 
H2O2 or organic hydroperoxides to water or corresponding alcohols using reduced 
glutathione (GSH) as an electron donor (H2O2 + 2GSH → GS-SG + 2H2O). 
(Margis et al. 2008). 
Catalase  
Catalase is an enzyme that is responsible for the conversion of hydrogen peroxide 
to water. It is localised in peroxisomes and may also be found in cytoplasm and 
mitochondria. (Dröge et al 2002). 
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Non enzymatic Antioxidants 
GSH  
The main antioxidant in the central nervous system, glutathione (GSH), is the 
most abundant antioxidant small molecule (Dringen 2003). It consists of a 
tripeptide of glutamate, cysteine and glycine and is particularly interesting in the 
context of PD because it has been found a marked depletion of this molecule in 
substantia nigra of PD patients. (Barker et al. 1996) 
Vitamin E  
The role of vitamin E in the central nervous system is not fully understood 
although it is a lipid soluble molecule with antioxidant function. It appears to 
neutralize the effect of peroxide and prevent lipid peroxidation in membranes. 
 
1.4.4 Mitochondrial dysfunction 
 
Mitochondrial dysfunction was proposed as one of the possible mechanisms that 
triggers and is part of the progression of PD. Strong evidence exists to support a 
role for aberrant mitochondrial form and function, as well as increased oxidative 
stress, in the pathogenesis of PD (Beal MF. 2007, Schapira 2008) There is 
complex link between mitochondria and other cellular machinery that affects cell 
survival, being that mitochondria have different important roles. First they have a 
key role in oxidative phosphorylation leading to the production of ATP, but they 
are also the main cellular source of free radicals, and they are involved in calcium 
homeostasis and in the regulation of cell-death pathways.  
Furthermore, several genes involved in the genetic forms of PD are involved in 
the balance of mitochondrial fission and fusion, thus affecting the maintenance of 
these organelles. (Henchcliffe et al. 2008, Exner et al. 2012 ). Mitochondria are 
important source of energy for the cells, and an energy failure leads to an 
impairment of several cellular functions such as ubiquitin-proteasome system and 
the release of dopamine from synaptic vesicles. The first link between Parkinson’s 
disease and the mitochondrial dysfunction was found in 1980s, when it was 
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discovered that the compound MPTP, an analog of meperidine, leads to features 
that mimic Parkinsonian syndrome, in particular inhibiting the mitochondria 
respiration (Langston et al. 1983, Nicklas et al. 1985). In vivo, MPTP is converted 
to MPP+ by MAO-B in glial cells, then, it is transported into neurons by 
catecholamine transporters, and there it exert its toxicity by inhibiting complex I. 
This leads to an increase production of ROS and ATP depletion. MPTP, since its 
discovery, was used to generate several PD model aiming to mimic features of 
this pathology (Schober 2004). Another compound used in PD research is 
rotenone, an insecticide that is also a complex I inhibitor. Epidemiological studies 
have implicated a link between rural environment and the related exposure to 
herbicides and pesticides with an elevated risk of PD ( Tanner et al. , 1999 )  
 
 
Fig. 6. Schematic representation of genes implicated in the mitochondria network. (Exner 
2012). 
 
In the following years, more precisely in 1989 a defect was first identified in the 
complex I of the sustantia nigra of PD patients (Schapira et al. 1990, Schapira et 
al. 1989, Mann et al. 1994) but the cause of this deficiency is not understood 
(Greenamyre et al. 2001. Further, mitochondria oxidative phosphorylation 
depends on both mitochondria and nuclear DNA-encoded proteins. Mutations in 
mitochondrial DNA (mtDNA) support the fact that alteration in the mitochondria 
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genome causes respiratory defects and phenotype typical of ageing process and 
age-related diseases. (Park and Larsson 2011) 
1.4.5 Dopamine 
 
Dopamine (DA) is a neurotransmitter that account for a variety of function 
through the body. In the central nervous system (CNS), dopamine is involved in 
the regulation of movements (nigrostrial pathway) and motivated behavior 
(mesolimbic pathway). Parkinson’s disease is a neurodegenerative disorder that is 
characterized by the preferential degeneration of dopaminergic neurons in 
substantia nigra pars compacta. Different mechanisms have been proposed to 
elucidate the start and the progression of the pathology. Since all the mechanisms 
proposed do not explain alone the susceptibility of dopaminergic neuron loss, the 
main working hypothesis is that dopamine itself could present potentially toxic 
characteristics (Graham 1978) Beside the great attention focused on the 
production of reactive oxygen species (ROS) during dopamine metabolism, 
growing evidence suggest that this neurotransmitter itself may play a direct role. 
Under physiological conditions, dopamine is synthesized in the cytosol from L-
tyrosine by the action of the enzyme Tyrosine hydroxylase to form L-
Dihydroxyphenylalanine (L-DOPA) that is converted to dopamine by the enzyme 
aromatic L-amino acid decarboxylase (AADC). Upon synthesis, dopamine is 
transported from the cytosol into synaptic vesicles by the vesicular monoamine 
transporter 2 (VMAT2) where it is stabilized by the low pH. Upon the arrival of 
an action potential, dopamine is released in the synaptic cleft to exert its function, 
after that it is uptaken via the dopamine transporter and recycled in new synaptic 
vesicles. If the amount of cytosolic DA exceeds the physiological concentration, 
DA is metabolized into the non-toxic metabolite 3,4-dihydroxyphenylacetic acid 
and hydrogen peroxide by the action of monoamine oxidase (MAO) and aldehyde 
dehydrogenase, or sequestered into lysosomes where it can auto-oxidize to form 
neuromelanin (NM). If not buffered by these pathways, cytosolic DA can be 
oxidized to DA-quinone (DAQs) (spontaneously or enzymatically), a reaction that 
also leads to the formation of ROS. 
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Dopamine oxidizes producing dopamine-o-quinone (DQ), which cyclizes to 
leukoaminochrome. The latter oxidizes to aminochrome (AC) rearranging to 5,6-
dyhydroxindole (DHI). The subsequent oxidation of DHI leads to the formation of 
indole-5,6-quinone (IQ) which polymerize to form neuromelanin. (Grahm 1978; 
Hastings 1995; Tse 1976).  
 
 
Fig. 7. The dopamine auto-
oxidation pathway. 
Dopamine oxidizes to dopamine-o-
quinone (DQ), which cyclizes to 
leukoaminoscrhome. Upon oxidation 
leukoaminochrome is converted into 
aminochrome (AC), which 
rearranges to 5,6-dyhydroxindole 
(DHI). DHI can be oxidized into 
indole-5,6-quinone (IQ) and 
polymerase to neuromelanin. 
(Bisaglia et al. 2007) 
 
 
The oxidation process of dopamine is accelerated by the presence of transition 
metal ions such as iron, copper and manganese (Sulzer and Zecca 2000) and by 
the presence ho peroxynitrite (LaVoie and Hastings 1999). Dopamine-quinones 
(DAQs) are electron-deficient and are able to react with cellular nucleophiles, 
such as cysteine residues of proteins. 
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Fig. 8. Schematic representation of the oxidation of dopamine (DA) to dopamine-quinone (DQ) 
and its chemical reaction with cysteine residues. (Adapted for LaVoie 2005) 
 
The covalent modification of these cysteine residues leads to the formation of 5-
cysteinil-dopamine adduct leading to an impairment or a block of the proteins 
activities, since cysteine residues are often localized in the active site of proteins 
(Asanuma 2003). It has been demonstrated that different proteins are affected by 
the DAQs modification, such as, DJ-1, SOD2, α-synuclein, Parkin and UCH-L1 
(Girotto 2012, Belluzzi 2011, Bisaglia 2007, Bisaglia 2010b, LaVoie 2005, Van 
Laar 2008, Van Laar 2009). 
 
1.4.6 Apoptosis in PD 
 
In response to excessive damage, or unfavorable intracellular or extracellular 
conditions, cells have evolved different mechanisms leading to cell death. 
Programmed cell death (PCD) is a conserved mechanism and plays a pivotal role 
in many physiological processes, especially during development and in 
maintaining cellular homeostasis. On the other hand, there is evidence that such 
mechanism is implied even in neurodegenerative disorders such as Parkinson’s 
disease. Numerous assays were developed to detect and quantify apoptosis such as 
ultra structural analysis of cell morphology, detection of caspases activation and 
their substrates cleavage, DNA fragmentation and mitochondrial functionality. 
The involvement of apoptosis in PD, first came by from the observation that the 
MPTP toxin-model for PD leads to the appearance of classical features of this 
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kind of programmed cell death (DiPasquale et al. 1991). However,  post-mortem 
studies on brains of PD patients, lead to conflicting conclusions on role for 
apoptosis in the neurodegeneration of dopaminergic neurons. Several laboratories 
found apoptotic neurons (Mochizuki et al. 1996, Anglade et al 1997, Tompkins et 
al. 1997) in the PD patients, but other could not replicate this findings (Banati et 
al. 1998, Wüllner et al. 1999) generating a debate on the matter that is still open.  
The progress of the tools used to detect apoptosis with the identification of new 
and different markers, that combined allowed confirming the role for apoptosis in 
PD (Tatton et al. 2000, Tatton et al. 2003, Hartmann et al. 2000). Recently 
caspase-3, an effector enzyme in programmed cell death, was associated with 
Parkinson's disease on a post-mortem human brain study (Hartmann et al., 2000). 
 
1.4.7 Cellular models in the context of PD 
 
PD is a complex and multi factorial pathology that nowadays has no cure. In vitro 
models (establish cell line, primary cell culture or stem cells) have different 
advantage in understanding the molecular mechanism involved in this pathology. 
Besides to the limitations posed by a simple model, like the cellular models are, 
they have many advantages. The most prevalent PD cell models include non 
neuronal tumor cell lines such as pheochromocytoma (PC12) cells, neuronal 
tumor cell lines like human neuroblastoma (SH-SY5Y) cells and primary 
mesencephalic neurons. They are very useful model to mimic feature of PD since 
they can be used to evaluate toxic-insult, drugs screening with different compound 
and serves to investigate single pathogenic mechanism implications of genes or 
proteins. 
The effect of PD-related toxins and genes were widely investigated in 
catecholinergic human neuroblastoma cell lines, such as SH SY5Y, SK-N-BE or 
BE2-M17. Further, neuron-like cellular model are the PC12, a cell line derived 
from a pheochromocytoma of the rat adrenal medulla and MES, a hybrid rat 
mesencephalic-neuroblastoma cell line. 
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In addition to its possible application in the cure for PD, stem cells also represent 
a good candidate for the PD research. The possibility to reproduce in vitro models 
of dopaminergic neurons comes from the use of human induced pluripotent stem 
cells (iPS). To date, there’s much effort in obtaining a standard protocol to 
reproduce iPS phenotype to obtain patient-specific stem cell lines for studying 
various disease mechanism (Seibler et al. 2011). Primary neuronal cultures 
derived from animal model can improve the investigation on PD pathogenesis at 
cellular level but have the disadvantage that they are not human genetic based. 
SH SY5Y cell lines have been widely used as a PD model since it possess the 
complete dopaminergic system and have the advantage to present a human genetic 
background. This cell line has been used primary for reproducing the impaired 
dopamine homeostasis since they present a good activity of the dopamine 
transporter (DAT) and a low activity of the vesicular monoamine transporter 
(VMAT2) allowing to increase the cytoplasmatic dopamine concentration by its 
administration in the cell culture medium (Bossi et al 2010, Alberio, Colapinto et 
al. 2010). This cell line, can be differentiated using different compounds such as 
retinoic acid (RA), phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), 
brain derived neurotrophic factor (BDNF), dibutyryl cyclic AMP (dBcAMP), 
purine, or staurosporine (Singh 2007, Påhlman 1981, Cernaianu 2008, Kume 
2008, Guarnieri 2009 and Mollereau 2007) leading to a different morphological 
and biochemical phenotype. The debate on the use of undifferentiated and 
differentiated cells is still open, but in different studies, it has been demonstrated 
that undifferentiated cells are more susceptible to toxins, leading to the suggestion 
that this kind of cells are a better cellular model to study toxicity derived from 
internal and external toxins. (Cheung 2009).
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Aim of the thesis 
 
In Parkinson’s disease, the selectivity death of dopaminergic neurons of the substantia nigra pars 
compacta is ascribed to several mechanisms among them, oxidative stress and mitochondrial 
dysfunction play a pivotal role and are good candidates to interconnect both familial and sporadic 
forms of the disease. To explain the selectivity death of dopaminergic neurons, it has been proposed 
that dopamine could have a central role in the start and progression of the pathology. 
Several studies suggest that an increase in cytosolic dopamine concentration (that could derive from 
different mechanism such as an improper vesicular storage or catabolism) leads to the oxidation of 
the latter to toxic dopamine-quinones (DAQs) and reactive oxygen species production. The 
formation of the former is a process that can occur either spontaneously or by enzymatic catalysis. 
Several enzymes have been proposed to be responsible for the enzyme-mediated oxidation process 
of dopamine, among them tyrosinase (TY). This enzyme is the rate-limiting step for the production 
of melanin, but several studies suggest also a role in the oxidation of dopamine into DAQs leading 
to cellular toxicity. The presence of the mRNA and the active protein in substantia nigra was 
confirmed (Greggio et al. 2005)focusing attention on the tyrosinase-mediated oxidation of 
dopamine as an additional mechanism in the start and progression of the disease. The aim of this 
project was to evaluate the toxic effect of both auto and TY-mediated oxidation processes of 
dopamine and their effect on cell viability in a cellular model of PD: SH SY5Y. We were interested 
in estimating potential differences in toxicity between these two processes and the kind of cell death 
activate. The identification of a possible common denominator could lead to the development of 
drugs for the treatment of the disease. Since oxidative stress has been implied in PD 
etiopathogenesis, another part of the project was focused on the oxidative damage induce by 
dopamine and DAQs. Among the cellular antioxidant defense against the over production of 
reactive oxygen species, superoxide dismutases play a central role as scavenger of superoxide 
anion. On the premises that dopamine oxidation chemistry leads to the production of ROS, the role 
of oxidative stress as a trigger and amplification mechanism for PD and the crucial role for SODs 
proteins, the second part of the work was focused on the possible role of superoxide dismutases 1 
and 2 in protecting cells against the auto and TY-mediated processes of dopamine oxidation.
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2. Materials and methods 
 
2.1 Molecular biology 
 
2.1.1 Cloning of SOD1 and SOD2 sequence 
 
The Human SOD1 full length cDNA was amplified from pOTB7 (fig. 9) vector 
and the SOD2 full length cDNA from the pCMV-SPORT6 (fig. 10).  
 
Fig. 9. pOTB7 vector 
map for the 
amplification of SOD1 
full length cDNA. 
 
Fig. 10. pCMV-
SPORT6 vector map 
for the amplification 
of SOD1 full length 
cDNA. 
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The primer used for the amplification from the origin vector were designed to 
carry restriction site for EcoRI and BamHI (for SOD1) and EcoRI and AgeI (for 
SOD2) for the subsequent cloning of the proteins in the destination vector. In 
table 2. are listed the primer used for the amplification, the restriction site 
(underlined) and the melting temperature. 
primer N. Nt  Tm °C 
SOD1 Koz FOR (5’-3’) 
GGTGAATTCGTAATGGCGACGAAGGCCGTGTGC 
33 84.2 
SOD1 BamHI (5’-3’) 
GTTTATCAGGATCCATTTCTACAGC 
25 62.7 
SOD2 Koz FOR (5’-3’) 
GGTGAATTCAGCATGTTGAGCCGGGCAGTGTGC 
33 84.7 
SOD2-AgeI (5’-3’) 
ACCACCGGTCTTTTTGCAAGCCATGTA 
27 77.1 
 
Table 2. Primers (Sigma) used for the amplification of the SOD1 and SOD2 
sequences from the origin vectors. Restriction sites for the ligation in the 
destination vectors are underlined. (N. Nt = number of nucleotides, Tm = melting 
temperature.) 
 
2.1.2 Polymerase chain reaction (PCR) 
 
The polymerase chain reaction is a powerful technique which allows to obtain in 
vitro millions copy of a target segments between two regions of known sequence 
starting from few copies. Using the primers listed in table 2.2, the full leght cDNA 
sequence of SOD1 and SOD2 was amplified from the origin vector and cloned in 
the destination vectors carrying the GFP and RFP sequence respectively. The 
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SOD1 sequence was inserted at the C-terminus of the GFP sequence while the 
SOD2 sequence was inserted at the N-terminus of the RFP sequence. 
Approximately 1ng of the origin vector was mixed with dNTPs (10mM each), the 
pfu (Pyrococcus furiosus) polymerase (3U/µL), pfu reaction buffer 10x and 
10mM each of forward and reverse primers. The PCR program carried out by the 
termocycler (My cycler thermal cycler BIO-RAD9) was programmed to an intial 
denaturation at 95°C for 2’, then 25 cycles of denaturation (95°C for 30’’), 
annealing (51°C for 30’’) and extension (72°C for 1’). A final extension step was 
performed at 72°C for 10’. PCR products were analyzed by agarose gel 
electrophoresis and purified. The DNA was conserved at 4°C.  
 
2.1.3 DNA purification 
 
DNA purification was achieved using the kit Wizard ® SV Gel and PCR Clean-
Up System (Promega). The kit is based on the ability of the DNA to bind silica 
membranes of the minicolumn in the presence of choatropic salts. It consist in the 
addition of an equal volume of Membrane Binding Solution (guanidine 
isothiocyanate 4.5M, potassium acetate 0.5M, pH 5.0) to the DNA sample and the 
loading into the SV minicolumn. After two wash steps with Membrane Wash 
Solution (potassium acetate 10mM, pH 5.0, ethanol 80%, EDTA 16.7µM, pH 
8.0), the DNA was eluted with H2O mQ pH 8.4. 
 
2.1.4 DNA and vector enzymatic restriction 
 
Enzymes used for the DNA and vectors enzymatic restriction are summarized in 
the table 3. 
EcoRI BamHI AgeI 
G*AATTC 
CTTAA*G 
G*GATCC 
CCTAG*G 
A*CCGGT 
TGGCC*A 
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Tab. 3. restriction enzymes and respective recognition sites used for the cloning. 
The experimental protocols for DNA insert and vector digestion are summarized 
below: 
 
DNA insert (ng)  Vector 2µg 
   
Buffer 10x  Buffer 10x 
BSA 10X  BSA 10X 
EcoRI 1U  EcoRI 1U 
BamHI 1U (for SOD1) and AgeI 
(for SOD2) 
 BamHI 1U (for GFP vector) and AgeI (for 
RFP) vector 
Sterile H2O mQ to final volume 
(50uL) 
 Sterile H2O mQ to final volume (50uL) 
 
All the reaction were kept at 37°C for 1-2 hours. 
To verify the result of digestion, small aliquots of restricted DNA and vector were 
loaded on agarose gel electrophoresis, and restricted DNA was purified to 
eliminate endonucleases. 
 
2.1.5 Vector dephosphorylation 
 
During ligation, DNA ligase will catalyze the formation of a phosphodiester bond 
between adjacent nucleotides only if one nucleotide contains a 5'-phosphate group 
and the other a 3'-hydroxyl group. Recircularization of plasmid DNA can 
therefore be minimized by removing the 5' phosphates from both ends of the 
linear DNA with calf intestinal phosphatase. As a result, neither strand of the 
duplex can form a phosphodiester bond. However, a foreign DNA segment with 
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5'-terminal phosphates can be ligated efficiently to the dephosphorylated plasmid 
DNA to give an open circular molecule containing two nicks. Because circular 
DNA (even nicked circular DNA) transforms much more efficiently than linear 
plasmid DNA, most of the transformants will contain recombinant plasmids. Up 
to 1µg of each vector was incubated at 37°C for 15 minutes and then at 74°C for 
15 minutes in a mixture containing 27 units of TSAP (Thermosensitive Alkaline 
Phosphatase), reaction buffer 10x and sterile H2O mQ to final volume 50 µL. 
 
2.1.6 DNA ligation 
 
To obtain the insertion of the SOD1 and SOD2 sequence in the destination vectors 
was performed DNA ligation. To estimate the amount of vector and insert to use, 
the following formula was used: 
 
          
                              
           
 
 
50ng of each destination vectors were incubated at room temperature for 2 h in a 
mix containing the amount (ng) of each insert (calculated before), T4 DNA ligase 
(from 0.1 up to 1 unit), ligase reaction buffer 10x and sterile H2O for a final 
volume of 15 µL. A reaction of auto ligation was carried out (as negative control) 
in the presence of the vector without the insert to estimate the yield of the vector 
self-ligation. Afterwards, E. coli DH5α were transformed with both the ligation 
products using kanamycin antibiotic (25µg/mL). The destination vector maps are 
listed below (fig. 11 and 12) and in the red boxes are highlighted the restriction 
sites for the cloning procedure. For the properly folding of SOD1, the fluorescent 
tag was cloned upstream to the SOD1 sequence, while for SOD2, the cDNA 
sequence was cloned at the C-terminal sequence of the fluorescent tag to preserve 
the correct translation of the mitochondrial tergeting sequence of the gene. 
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Fig. 11. Destination vectors for the expression in a mammalian cell line of pACGFP1-C2 for 
SOD1 cloning. In red boxes are highlighted the restriction site for the cloning procedure. 
 
 
Fig. 12. Destination 
vectors for the 
expression in a 
mammalian cell line of 
pDsRed1-N1 for SOD2 
cloning. In red boxes 
are highlighted the 
restriction site for the 
cloning procedure. 
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2.1.7 Bacterial transformation 
 
For bacterial transformation an aliquot of 100 µL  of frozen E. coli DH5α 
competent cells were kept in ice for 10’. Afterwards 1 µL of ligation was used to 
transform the cells. After the addition of DNA, the cells were left in ice for 20’. 
The aliquot was incubated for 90’’ at 42°C (thermal shock) and then placed in ice 
for 2’. A 900 µL of Luria Bertani (LB) medium was added at the aliquot and 
incubated at 37°C for 1 hour. Subsequently the aliquot was centrifugated at 
3000rpm for 2’. The supernatant was discarded and bacterial resuspended in 100 
µL were plated in a LB agar plate containing kanamycin (25 µg/mL) and left 
overnight at 37°C. 
 
2.1.8 Bacterial colonies screening 
 
After the transformation the colonies were screened to select those that have 
incorporated the insert. For this purpose, the colonies were picked up, and used as 
template to perform a PCR reaction. Each colony was added (as template) in a 
mix containing reaction buffer 10x, dNTPs 10mm (each), forward and reverse 
primers (10mM each), MgCl2 (25mM), Go Taq polymerase (5 unit/µL) and sterile 
H2O mQ to final volume of 15 uL. The thermocycler program used was the 
following: 
 
 
 
 
 
PCR product 
were loaded 
on an agarose gel to evaluate which colonies were positive. Those colonies that 
have incorporated the insert were inoculate in LB medium containing kanamycin 
 T = °C time  
Denaturation 95°C 2’  
Denaturation 95°C 30’’  
Annealing 51°C 30’’   For 25 cycle 
Extension 72°C 1’  
Extension 72°C 10’  
Materials and methods 
 
42 
 
antibiotic and left overnight at 37°C for small-scale purifications of plasmid DNA 
(minipreps).  
 
2.1.9 Plasmid DNA extraction 
 
After overnight shaking at 37 °C, cells were centrifuged at 3000 g for 5 minutes. 
The LB broth was discarded and the cells were gently resuspended in 250 μl of 
Cell Resuspension Solution, an isotonic buffer (see below). Cell Lysis Solution 
(250 μl), containing SDS to disrupt the cell and NaOH to denaturate DNA, was 
added. At interval of 5 min each, the following solutions (composition described 
below) were added: 10μl of Alkaline Protease Solution to inactivate 
endonucleases; 350μl of Neutralization Solution to neutralize the pH. The lysate 
was centrifugated at 14000 g for 10 minutes to separate the DNA in the 
supernatant from the lipids, proteins and genomic DNA of the cells. The 
supernatant, was loaded into the spin column , a chromatographic anion exchange 
column (Promega Wizard® Plus SV Minipreps DNA Purification System kit). 
The DNA binds to the column and after two step of wash with Column Wash 
Solution, the DNA was eluted in sterile H2O mQ pH 8.4.  
 
Buffer composition: 
Cell Resuspension Solution: Tris(hydroxymethyl)aminomethane (Tris-HCl) (pH 
7.5), 50mM Ethylenediaminetetraacetic acid (EDTA) 10mM, RNase A 100μg/ml. 
Cell Lysis Solution: sodium hydroxide 0.2M and sodium dodecyl sulphate (SDS) 
1%. 
Neutralization Solution: potassium acetate (pH 4.8) 1.32M. 
Column Wash Solution: potassium acetate 80mM, Tris-HCl (pH 7.5) 8.3mM, 
EDTA 40μM and ethanol 55%. 
 
For high-scale DNA purification, midi or maxipreps were performed according to 
the manufacturer instructions.  
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2.1.10 DNA quantification 
 
DNA quantification is necessary to ascertain the approximate quantity of DNA 
obtained for further analysis. Two methods were used: spectrophotometric 
analysis and gel electrophoresis. The first one consists in measuring the 
absorbance of DNA solution at 260nm, where DNA shows an absorption maxima. 
Since an absorbance of 1 corresponds to a concentration of 50 ng of 
doublestranded DNA in solution, the concentration of DNA in solution can be 
easily calculated using the following formula: 
 
ng/μl of dsDNA = (A260nm× c) × dilution factor 
 
Moreover, the purity of the sample, in terms of proteins contamination, can be 
calculated from the ratio of OD260/OD280. A pure DNA preparation has a value 
around 1,8. The second method with gel electrophoresis (see 2.1.7) consists in the 
comparison on the transilluminator of the sample with standard DNA (plasmids or 
PCRs, depending of the type of the sample) previous quantified. This method is 
very sensitive, since it allows to quantify down to few nanograms of DNA. 
2.1.11 Agarose gel electrophoresis 
 
Agarose (Applichem) was dissolved in the suitable electrophoresis buffer 
TAE 1X. Agarose concentrations were 1% for DNA plasmids of 5-6 kbp and 2% 
to analyze DNA fragments of 0,1-1 kbp. The mixture was heated in a microwave 
oven until completely melted, then was poured into a casting tray containing a 
sample comb. Once the gel has cooled at room temperature, the comb was 
removed and the gel placed into an electrophoresis cell, filled with TAE 1X 
buffer. Before loading the DNA samples into the wells with a micropipette, it was 
necessary mix the samples with loading dye (Promega), a colored loading buffer 
containing glycerol and DNA intercalant, which enables to track the running of 
the gel and to visualize the bands under UV illumination. Beside to DNA samples, 
an appropriate molecular weight standard, the 100bp or 1kbp DNA ladder (fig. 
2.3), was loaded in order to identify the size of DNA samples by comparison with 
the fragments of known size. At this point, a current field, between 50-100 volts 
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depending on the gel size, was applied to gel until the bromophenol blue front of 
the loading dye was migrated about 70-80% toward the positive pole. At the end 
of the running, the gel was placed on a UV transilluminator to visualize the DNA 
due to the presence of the DNA intercalator. 
 
Buffer composition: 
TAE 1X: Tris-Acetate 40mM, EDTA 1mM, pH 8.3. 
Loading dye 6X (Promega): orange G 0.4%, bromophenol blue 0.03%, xylene 
cyanol FF 0.03%, Ficoll® 400 15%, Tris-HCl (pH 7.5) 10mM and EDTA 50mM 
(pH 8.0). 
 
2.1.12 DNA sequencing 
 
The PAcGFP-C2 vector containing the SOD1 insert and the pDsRed1-N1 vector 
containing the SOD2 insert were dried at 65°C and sequenced by BMR Genomics 
(spin-off of University of Padova) to verify the exact sequence and the right frame 
of the two fusion protein. 
 
2.1.13 RNA extraction  
 
Cells were lysed directly in a culture dish by adding 1 mL of TRIZOL Reagent to 
a 3.5 cm diameter dish, and passing the cell lysate several times through a pipette. 
The amount of TRIZOL Reagent added is based on the area of the culture dish (1 
mL per 10 cm2). The sample was homogenized for 5 minutes at 15 to 30°C to 
permit the complete dissociation of nucleoprotein complexes. 0.2 mL of 
chloroform were added per 1 mL of TRIZOL Reagent. Tubes were shaked 
vigorously by hand for 15 seconds and incubate at 15 to 30°C for 2 to 3 minutes. 
Samples were centrifuged at 12,000 x g for 15 minutes at 2 to 8°C. Following 
centrifugation, the mixture presented a lower red, phenol-chloroform phase, an 
inter phase, and a colorless upper aqueous phase. RNA remains exclusively in the 
aqueous phase. The aqueous phase was transferred to a fresh tube and precipitated 
from the aqueous phase by mixing 0.5 mL of isopropyl alcohol per 1 mL of 
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TRIZOL Reagent used. Samples were incubated at 15 to 30°C for 10 minutes and 
then centrifuged at 12,000 x g for 10 minutes at 2 to 8°C. The supernate was 
removed and the RNA pellet was washed once with 75% ethanol, adding at least 1 
mL of 75% ethanol per 1 mL of TRIZOL Reagent used. The sample was mixed 
by vortexing and centrifuged at 7,500 x g for 5 minutes at 2 to 8°C. At the end of 
the procedure, the RNA pellet was air-dried for few minutes and dissolved in 
RNase-free water and incubated for 10 minutes at 55 to 60°C.  
The integrity of the RNA was assessed by agarose gel electrophoresis, and the 
concentration was calculated by UV spectroscopy. 
 
2.1.14 mRNA retrotranscription 
 
for the amplification of dopaminergic markers, mRNA was retrotranscribed to 
obtain cDNA.Up to 1µg of RNA was mixed with 10mM of random primers (mix 
I). The mix was incubated for 5’ at 70°C and then chilled for 5’ at 4°C. afterwards 
in the first mix were added the reaction buffer 5x, 40mM MgCl2, dNTPs 10mM 
each, RNasin® Ribonuclease Inhibitor (24 units), RT polymerase (18 units) and 
H2O to final volume of 15µL. The final mix was placed in the thermocycler and 
the program used is listed below 
 
25°C for 5’ 
42°C for 60’ 
70°C for 15’ 
Preserve at -20°C 
 
2.1.15 Amplification of dopaminergic markers 
 
primers used for the amplification of dopaminergic markers are listed in the table 
below (tab. 4.) 
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Oligo name Sequence (5’-3’) 
  
TH for CACAGGCCAAGGGCTTC 
TH rev TCCTCGATGAGGCTCTGC 
AADC for GAAGCCCTGGAGAGAGACAA 
AADC rev CCTTGTTGCAGATAGGACCG 
DAT for CACCTGCTGCCGAGTACTTT 
DAT rev TAGAGCAGCACGATGACCAG 
VMAT2 for CCGACTGTCCCAGTGAAGAC 
VMAT2 rev CGCAAATATGGGAATTGGAT 
DBH for GCCTTCATCCTCACTGGCTA 
DBH rev TTCTCCCAGTCAGGTGTGTG 
GADPH for AATGAAGGGGTCATTGATGG 
GADPH rev AAGGTGAAGGTCGGAGTCAA 
SOD1 for GCATCATCAATTTCGAGCAG 
SOD1 rev GACCTGCACTGGTACAGCCT 
SOD2 for CACCGAGGAGAAGTACCAGG 
SOD2 rev TAGGGCTGAGGTTTGTCCAG 
 
Tab. 4. Primer sequences for the amplification of dopaminergic markers. 
 
The mixture for the amplification of dopaminergic markers comprises: Nuclease 
free water (to the desired volume), 10x thermophilic polymerase reaction buffer, 
2mM MgCl2, 0.2mM Nucleotide mix, 1µM upstream and downstream primers 
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each and 5 units/µL of Taq DNA polymerarse. The thermocycler program is 
reported below  
Denaturation 94°C for 2’ 
Denaturation 94°C for 1’ 
Annealing 55°C for 45’’ 
Extension 72°C for 2’ 
Finale extension 72°C for 7’ 
Hold 4°C 
 
2.2 biochemistry 
 
2.2.1 SDS-PAGE and western blotting 
 
Briefly, cells were trypsinized, centrifuged and resuspended in 100 uL lysis buffer 
(20mM Tris pH 8.0, 150mM NaCl 1mM EDTA, 1% Triton and protease inhibitor 
cocktail) to prepare whole-cell lysates and maintained in ice for 30’. Subsequently 
lysates were centrifugated at 13.000g for 30’ to remove cell debris and the 
surnatant was collected. Protein concentration was determined by the BCA 
method (BCA protein assay kit, Thermo Scientific). Total protein cell lysate were 
separated in a 4-20% SDS-PAGE gels and transferred to a nitrocellulose 
membrane.  The membranes were probed with different primary antibodies 
(1:1000) for 1 hour or overnight where needed. Mouse anti-β tubulin (1:2000) was 
used as internal control. The incubation with primary antibody was followed by 
horseradish peroxidase conjugated secondary antibody (1:2000),  and developed 
with the ECL system (Ge Healthcare). 
 
For 35 cycles 
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2.3 Cellular Biology 
 
2.3.1 Splitting adherent cell lines by trypsinisation 
 
Cells which grow in monolayer culture are usually split (= passaged)  to provide 
new stock flasks when they are covering the whole of the culture surface (= 
confluent).  Failing to split cells can result in the cells either overgrowing and/or 
cell death. The media from the flask containing cells was removed and a volume 
of trypsin (enough volume to cover the layer) was added and left 1-2’ at 37°C to 
let the enzyme to detach cells. Afterwards, trypsin was inactivated adding enough 
volume of serum-containing medium and the cells suspension was pipetted up and 
down to avoid the formation of cell clumping. The desired volume of cells were 
placed in a new flask to allow them to replicate. 
 
2.3.2 Poly-lysine coating tissue culture vessels 
 
The poly-lysine coating allows to attach cells to coverslips and perform 
fluorescence microscopy and immucytochemistry techniques. Coverslips were 
sterilized sinking them into ethanol 70% and subsequently placing them into a 12-
well plate under UV illumination. After the sterilization passage, poly-lysine was 
added in a volume enough to cover the coverslips and the plate was incubated for 
30’ in the incubator at 37°C. After the incubation, poly-lysine was removed and 
the coversplips were washed twice with mmQ water. The coversplips were left to 
dry in sterile conditions and subsequently, 3x10
5 
were seeded and left to reach the 
desired confluency ( approximately 60%). 
 
2.3.3 Transient transfection (lipofectamine) 
 
For transient transfection, 3x10
5
 cells were seeded in a 6-well plate on coversplips 
and left to reach approximately 60% of confluence. The day of the experiment, the 
medium of the cells were replaced with Optimem. In separate tubes, 4uL of 
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lipofectamine were incubated in 100uL of optimem for 5’ at room temperature. At 
the same time, 2ug of DNA (vectors for the transfection) were added to 100uL of 
optimem. After the incubation, the DNA and the lipofectamine were mixed to let 
the formation of DNA-lipofectamine complexes and incubate at room temperature 
for 30’. Subsequently the mix was added to the cells and left for 3h in the 
incubator. Afterwards the medium (optimem + DNA-lipofectamine mix) was 
replaced with fresh cell culture medium. All the treatments for the experiments 
were performed 36h after the transfection. 
 
2.3.4 Paraformaldehyde recipe 
 
50mL of distilled water were heat till 50°C, and subsequently 4g of 
paraformaldehyde were added and stirred.  (do not heat above 70°C). Several 
drops of 1M NaOH were added until the solution was transparent. The solution 
was left to chill. 10mL of PSB 10X were added and the pH was checked (around 
7.2-7.4) and corrected where necessary. Distilled water was added to reach a final 
vlume of 100mL. Aliquots were preserved at -20°C and thawed at room 
temperature. 
 
2.3.5 Hoechst Staining for Nuclear Fragmentation 
 
Hoechst 22432 is a cell permeable DNA binding dye that gives a blue 
fluorescence when excited by UV light.  Identifying cells undergoing apoptosis 
(chromatin condensation and fragmentation) is relatively easy once stained with 
Hoechst. This can also be used as a nuclear counterstain for immunofluorescence. 
The cells were left to grown on coverslips till 60% of confluence, and 
subsequently treated with different conditions. The day after, cells were fixed with 
paraformaldheyde 4% for 20’ at room temperature. Then they were stained with 
1ug/uL Hoechst in PBS, for 5 minutes at room temperature. Finally they were 
mounted over a glass slide and examined under UV illumination. 
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2.3.6 Mitosox probe 
 
For the evaluation of mitochondrial superoxide anion production, we used 
mitosoxRed. The probe was resuspended in DMSO to obtain a 5mM stock. For 
the experimental condition the probe was used at 5uM concentration and 
incubated for 30’ at 37°C in the incubator prior the treatments. 
 
2.3.7 Time-lapse imaging of superoxide anion production  
 
For the time-lapse imaging, 1x10
6 
were seeded in a 35mm plate and left to reach 
80% confluency. The day of the experiment, 5uM of MitosoxRed was added to 
the medium and left to incubate at 37°C for 30’ (in the incubator). After the 
incubation of the probe, the treatment was added in the cell medium. The well was 
left in a thermostatic chamber as in the growth condition and the microscope 
(Leica Microsystems DM4000) was programmed to take photos in the bright field 
(BF) and in the red channel (N21) every 10 minutes for 15h. the microscope 
parameters are summarized in the table below (tab. 5) 
 
Channel objective gain exposure 
 
BF (brighfield) 
 
40X 
 
2 
 
25 
N21 (red) 40X 4.2 910 
Tab. 5 microscope parameters. 
 
2.3.8 Flow cytometry 
 
Flow cytometry is a laser based, biophysical technology employed in cell 
counting, sorting, biomarker detection and protein engineering, by suspending 
cells in a stream of fluid and passing them by an electronic detection apparatus. It 
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allows simultaneous multiparametric analysis of the physical and/or chemical 
characteristics of up to thousands of particles per second. Several information can 
be extrapolated from the analysis, such as morphological parameters and 
fluorescence properties. 
2.3.9 Cell detachment method evaluation 
 
Since Flow cytometry was conceived for the analysis of cells grown in 
suspension, and the detachment of adherent cells leads to stress and false positive 
data, we evaluate the method of cell detachment that give rise to the low 
background in our control samples (both for ANNEXIN+PI and Mitosox). The 
day before the experiment, 1x10
6 
were seeded in a 6-well plate to reach 
approximately 80% of confluence. The next day, floating cells were collected and 
centrifuged at 1000g for 5’. The adherent cells were detached from the plate with 
four different methods that are listed in the table below (tab 6) 
 Cell detachment method Time  inactivation 
    
mechanical Pipetting using PBS 5’  
chemical EDTA(0.05mM) in PBS 5’  
enzymatic Trypsin (0.25%) 5’ DMEM containing serum  
enzymatic Papain (12U/mL) 5’ DMEM containing serum 
 
Tab. 6 cell detachment methods. 
The adherent cells were added to the floating ones and centrifuged for 5’ at 1000g. 
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2.3.10 Fluorophore staining 
 
Mitosox labeling: the day before the experiment, cells were incubated for 30’ with 
the mitosox probe and then treated with the different conditions overnight. The 
day after cells were analyzed with FACS (BD FACSCanto II). 
Annexin-PI labeling: cells were resuspended in HBSS solution with 1uL/500uL of 
ANNEXIN-V-FLUOS and with 1uL/500uL of PI and incubate at 37°C for 15’ in 
the dark. Afterwards cells were transferred in FACS tube and analyzed. 
 
2.3.11 Treatments 
 
Nuclear fragmentation 
For the experiments on nuclear fragmentation, both naïve cells and cells over 
expressing SODs and the respective negative control, were treated with increasing 
concentration of dopamine: from 0µM to 150 µM. In the case of DAQs, cells 
were treated with the same concentration of dopamine and the units of tyrosinase 
to use were calculated in respect to the dopamine concentration to obtain the 
complete oxidation of dopamine in 30 minutes. In the case of treatment with the 
DAT inhibitor (on naïve cells), cells were pre-treated for 30’ with 100nM of GBR 
12909. 
 
Time-lapse imaging 
For the experiments of time-lapse imaging cells were treated with dopamine 100 
µM, 15Units of tyrosinase, GBR 12909 100nM, and antimycin A 100 µM. 
Flow cytometry 
Annexin-PI: 1x10
6 
cells were seeded in a 6-well plate and let to reach 
approximately 62% of confluence. The day before the experiment, cells were 
treated with 100µM and 200 µM dopamine, 15Units of tyrosinase (only in the 
case of dopamine 100 µM), GBR 12909 100nM, staurosporine 500nM and 1 µM. 
Materials and methods 
 
53 
 
Mitosox: 1x10
6 
cells were seeded in a 6-well plate and let to reach approximately 
62% of confluence. The day before the experiment, cells were pre-treated with 5 
µM of MitosoxRed probe, afterwards they were treated with 100µM and 200 µM 
dopamine, 15Units of tyrosinase (only in the case of dopamine 100 µM), GBR 
12909 100nM, antimycin A 100 µM and 200 µM. 
 
Western blot analysis 
1x10
6 
cells were seeded in a 6-well plate and let to reach approximately 60% of 
confluence. The day before the experiment, cells were treated with dopamine 100 
µM and 200 µM, 15Units of tyrosinase (only in the case of dopamine 100 µM), 
GBR 12909 100nM, staurosporine 500nM and antimycin A 100 µM 
 
2.4 Statistical analysis 
 
Statistical analysis was performed with the GraphPad Prism software (version 
5.0). Values in the histograms represents media and ± SEM. T-student test was 
applied when two groups were compared, whereas two-way ANOVA followed by 
Bonferroni post-hoc test in the case of multiple comparisons. P values were 
considered as described below: 
 
P value Wording Summary 
   
< 0.001 Extremely significant *** 
0.001 to 0.01 Very significant  ** 
0.01 to 0.05 Significant * 
>0.05 Not significant n.s. 
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3. Results 
 
3.1 evaluation of the cellular model 
 
With the purpose to dissect the molecular pathway of cellular toxicity induced by dopamine and its 
oxidized forms and to evaluate the role of superoxide dismutases 1 and 2 in protecting cells, we 
used a cellular model: SH SY5Y. This cell line is widely used in PD model since it expresses all the 
dopaminergic machinery, and have the advantage that is genome human-based. Before starting any 
experiment, we were interested in testing our cellular model for the presence of all the protein 
involved in the dopaminergic system machinery. For this purpose, the RNA was extracted, mRNA 
was retrotranscribed  to obtain cDNA and the dopaminergic markers were amplified with specific 
primers (fig. 7). Although this kind of analysis permits to obtain only information on  the 
expression of the mRNA of the different proteins, from the data obtained we concluded that our 
cellular model has the entire dopaminergic system that allow us to proceed to the next experiments. 
 
 
 
Fig. 7. SH SY5Y possesses all the dopaminergic system machinery. agarose gel of RNA extracted from SHSY5Y cell 
line and amplification products of dopaminergic markers. Tyrosine hydroxilase (TH), L-amino acid decarboxylase 
(AADC), Dopamine β-hydroxylase, vescicular monoamine oxydase (VMAT2), dopamine transporter (DAT), 
superoxide dismutase 1,2 (SOD). Glyceraldehyde 3-phosphate dehydrogenase (GADPH) was used as positive control. 
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3.2 Evaluation of dopamine and dopamine-quinones citotoxicity 
 
3.2.1. Evaluatation of apoptotic nuclei by Hoechst staining 
 
To evaluate the citotoxicity effect of dopamine and its oxidized forms, dopamine-quinones (DAQs), 
we used different techniques. Since in literature is reported that the loss of dopaminergic neurons in 
Parkinson’s disease is caused by the activation of the apoptotic pathway, we evaluate several 
markers of apoptosis. At first we were interested in confirming the activation of apoptosis in 
dopamine and DAQs induced cell death and therefore we evaluate one of the last sign of apoptosis: 
apoptotic nuclei. Using the DNA-binding dye Hoechst staining, we performed a fluorescence 
microscopy experiment to evaluate the morphology of nuclei after dopamine and DAQs treatment. 
In the first experiment we evaluate the toxicity of dopamine in inducing apoptotic cell death. The 
physiological concentration of dopamine inside cells has been reported to be in the nM range, 
reaching a mM concentration inside the synaptic vesicles. (Eisenhofer et al. 2004, Kopin et al. 1993, 
Santiago et al. 1996, West et al. 2003). These studies suggest that a slight increase in intracellular 
dopamine concentration could have important consequences on cell viability. For this reason we 
decided to treat cells with non-letal concentration of dopamine. SH SY5Y were treated with 
different concentration of dopamine (for a representative image see fig. 8) and the percentage of 
apoptotic nuclei was calculated. Dopamine induced cell death in a dose-dependent manner (fig. 9) 
 
 
Fig. 8. Dopamine induce apoptotic cell death. Representative image of nuclei morphology in control cells and in cells 
treated with dopamine (100µµM). It is possible to note the changes in the morphology of the nuclei that undergo a 
fragmentation in small bodies confirming the apoptotic cell death. In the right small boxes there is a zoom of the nuclei. 
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In the graph below is represented the statistical analysis if nuclear fragmentation after dopamine 
challenge (Fig. 9). 
 
Fig. 9 Dopamine induces apoptotic nuclei appearance in a dose-dependent manner. Percentage of apoptotic nuclei 
counted in cells treated with increasing concentration of dopamine. ( N = 3, t-test for the evaluation of statistical 
significance in respect to control, * p<0.05) 
 
Under physiological conditions, dopamine is stored in the synaptic vesicles by the action of 
vesicular monoamine transporter 2 (VMAT2) and upon the arrival of an action potential, dopamine 
is released in the synaptic cleft. Once it has exert its function is then recycled by the activity of the 
dopamine transporter and re-sequestered into the synaptic vesicles. A study of Manáková and 
colleagues (Manáková et al 2004) demonstrated a prominent role for the DAT in protecting cells 
against 6-OHDA. Other studies on dopamine toxicity led to controversial results with some 
showing no effect on inhibition of the dopamine transporter (Jiang et al. 2008) and others the 
contrary (Fazeli et al. 2011). Since in literature is still on debate the role of the DAT, and since we 
treated cells adding dopamine in the cell media (extracellular environment), we were interested in 
evaluating the role of the dopamine transporter (DAT) in mediating the dopamine-induced cell 
death in our  PD cellular model. The GBR 12909 compound have been reported to have high 
affinity and selectivity for the dopamine transporter, and a slow dissociation leading to a long-
lasting effect (Rothman 1991, Choi et al 1991) and in the study of Manáková concerning about the 
toxicity of 6-OHDA, the pre-treatment of cells with 100nM of the  dopamine transporter (DAT) 
inhibitor GBR 12909 rescued cells against 6-OHDA toxicity (Manáková et al 2004) . We pre-
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treated cells with 100nM GBR  and then we added dopamine. In the (fig. 10) is visible that the DAT 
inhibitor had a rescue effect against dopamine toxicity, we therefore concluded that dopamine needs 
to enter cells to exert its toxicity. 
 
 
Fig. 10 DAT inhibitor (GBR 12909) have a protective role against dopamine toxicity. Percentage of apoptotic nuclei 
counted in cells treated with dopamine and dopamine plus the DAT inhibitor GBR 12909. ( N = 3, * p<0.05) 
 
Once we demonstrated that extracellular dopamine exert its toxicity only in the case of its 
internalization in the cells, we tested if the enzyme-mediated oxidation of dopamine also leads to 
apoptotic cell death. Cytosolic dopamine cad undergo two different pathway of oxidation: by an 
auto-oxidation mechanism or a oxidation mediated by the action of enzymes. Several enzymes are 
responsible for the oxidation of dopamine. Monoamine oxidase A and Catechol-O-methyl 
transferase are responsible for the degradation of dopamine and dopamine that is not broken down 
by enzymes is repackaged into vesicles for reuse by VMAT2. It has been demonstrated that other 
enzyme are responsible for dopamine oxidation, among them tyrosinase, prostaglandin H synthase, 
xanthine oxidase (Sulzer and Zecca 2000; Asanuma et al. 2003). Tyrosinase has been implied as 
one of the enzyme responsible for the oxidation of dopamine to DAQs (Miranda and Botti 1983; 
Costa et al. 1992). In 1996 Stokes and colleagues observed that the formation of dopamine quinone 
is accelerate by the presence of tyrosinase in an in vitro model (Stokes et al. 1996). In another study  
Xu and collaborators showed that tyrosinase can enhance the concentration of dopamine quinone 
thus exacerbating the covalent binding and inactivation of TH via adduct formation (Xu et al. 
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1998). Tyrosinase may then function as a quinone generator within the dopaminergic neurons, but it 
was also reported to have a protective role. This enzyme could also contribute to NM formation, the 
synthesis of which is thought be driven by excess cytosolic dopamine not accumulated in synaptic 
vesicles (Sulzer et al. 2000). These considerations show that tyrosinase has a potential dual role: to 
damage neurons by producing dopamine-quinones or protect cells by enhancing NM synthesis. The 
expression of tyrosinase mRNA in the brain is a data supported by different studies (Xu et al. 1997; 
Tief et al. 1998), and the presence of a functional protein in this area was confirmed (Greggio et al. 
2005). On these premise, we wanted to evaluate the different mechanism of dopamine oxidation, 
therefore we treated cells with dopamine plus tyrosinase to oxidize dopamine in DAQs in a 
enzymatic way and we evaluate if there was a difference in the toxicity between the auto-oxidation 
and the enzyme-mediated process.The decision to use tyrosinase to oxidize dopamine was 
considered to compare the kinetics of production of DAQs species. As a enzyme-mediated reaction, 
the dopamine oxidation process by the action of tyrosinase was faster than the autoxidation one. It 
is possible to follow the kinetic of dopamine oxidation mediated by the tyrosinase enzyme using 
UV spectroscopy. The peak absorption at λ = 280 nm represent dopamine and it decreases through 
time indicating the disappearance of dopamine and immediately, an absorption maximum appears at 
λ =  395 nm, corresponding to the yellow dopamine-o-quinone chromophore (DQ), which is 
progressively replaced by the orange  aminochrome (AC). The kinetic of the tyrosinase-mediated 
oxidation of dopamine led to the complete stabilization of the AC within 30 minutes. Dopamine and 
DAQs treatment didn’t suggest a difference in the rate of toxicity (fig 11) 
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Fig. 11 Dopamine and DAQs do not display different toxicity in cells. Percentage of apoptotic nuclei counted in cells 
treated with dopamine and dopamine plus tyrosinase. ( N = 3, n.s. = p > 0.05) 
 
The positive control with the treatment of cells only with tyrosinase (in respect to dopamine 100µM 
concentration) showed also a toxic effect since in the cell medium is present L-tyrosine. Tyrosinase 
catalyze the idroxylation of L-tyrosine directly to dopamine quinones or indirectly to form before L-
DOPA and after dopamine quinones. Anyway, this data do not influence our results, since the ratio 
between tyrosinase units and different dopamine concentration is the same, and the increase in 
dopamine concentration led to a consequent increased in percentage of nuclear fragmentation in a 
linear manner. Our previous result demonstrate that dopamine requires to enter cells to exert its 
toxicity, since the pre-treatment with the DAT inhibitor had a protective effect on cell viability. We 
therefore asked if dopamine quinones toxicity dependes on the DAT internalization.The treatment 
with GBR did not show a difference in the toxicity between the DAT not inhibited and inhibited 
leading to the conclusion that dopamine quinones toxicity is not mediated by the dopamine 
transporter and presumably they permeate the cell membrane (fig 12). 
 
 
Fig. 12 DAQs toxicity is not mediated by the DAT internalization activity. Percentage of apoptotic nuclei counted in 
cells treated with dopamine and dopamine plus tyrosinase and the DAT inhibitor (N = 3, n.s. = p > 0.05). 
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The images of all the treatments and the relative morphology of the nuclei are summarized in figure 
13 
 
FIG. 13. Both dopamine and DAQs lead to nuclear fragmentation. Representative images of different treatments. It is 
possible to note that both dopamine and DAQs induce nuclear fragmentation and the treatment with GBR (dopamine 
transporter inhibitor) have a rescue effect only in the case of dopamine. In small boxer are zoom of the respective 
images. 
 
To confirm the activation of apoptotic pathway mediated by dopamine auto-oxidation and oxidation 
mediated by enzymes to generate dopamine-quinones, we evaluate another apoptotic marker with 
flow activated cell sorter: the externalization of phosphatidil-serine. (Vermesa 2000) 
 
 
Results 
 
62 
 
3.2.2 Flow cytometry 
For our experiment in the evaluation of apoptosis we performed a double labeling experiment using 
two different fluorophores: ANNEXIN-V -FLUOS for the detection of phosphatidil-serine 
externalization (an early marker of apoptosis) and propidium iodide (a marker for necrosis). Flow 
cytometry was conceived to analyze cells growing in suspension. The detachment of the adherent 
cells, required to use FACS, give rise to stress. To quantify the potential damage to adherent cells, 
we first evaluate which method of detachment was the best choice to minimize the level of 
background signal only due to the procedure. We evaluate four different methods: one mechanical 
using only PBS, one chemical using EDTA in PBS (0.05mM) and two enzymatic using tripsin 
(0.1mM) and Papain (12 U/mL). 
We choose this four methods because they represent the classical methods used to detach adherent 
cell and to test the sensitivity of our cells to the detachment procedure. PBS is used to detach cells 
in a mechanical way, but usually is not recommended for flow cytometric analysis since it give rise 
to high degree of damage to cell membranes. EDTA in PBS is used as a chemical method since this 
compound is a metal chelator and impedes to the cell adhesion molecule (CAMs), that depends on 
Ca
++ 
presence, to exert their function. The two enzymatic methods chosen were trypsin and papain. 
Both are enzyme typically used to detach adherent cells. In particular trypsin was used to passage 
cells when they were at confluency, while papain is usually used with very sensitivity cells or 
neuronal culture that are more susceptible to insults. (Panchision 2007) 
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fig. 14. Papain minimize the production of debris during the cells detachment procedure. In the image are reported the 
dot-plots of FSC and SSC, representing the morphological parameters of cells. In the control sample it is important to 
have the major percentage of cells in the P1 population that represent the ―healthy‖ population, while in the P2 
population are represented death cells and debris. The procedure of cell detachment could lead to a high background of 
cell debris therefore it is important to use the proper experimental procedure. 
 
The cell detachment method is crucial to proceed with the next experiments. In fig. 14 is evident 
that papain permits the proper detachment of cells and that the procedure maintain the 
morphological feature of healthy cells (P1 population), while the other methods led to a high level 
of cell debris (P2 population). In fig 15 is represented the peak of fluorescence intensity of the 
ANNEXIN-V  probe that is the marker of apoptosis. In control sample this peak is centered to zero 
values since all the cells do not exhibit fluorescence, while upon an apoptotic stimulus, the 
phosphatidil-serine externalization leads to the bond of the fluorescence probe that in the 
histograms is represented by the shift of the peak to higher values. Again papain showed a peak 
centered to zero values, allowing to proceed to the next experiment. 
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fig. 15. Papain exhibit the lower fluorescence background in control sample.  in this image is reported the fluorescent 
signal from the ANNEXIN-V  probe. In control sample the peak must be centered to zero values to appreciate its shift 
to higher values upon induction of apoptosis. 
 
 
Fig. 16 Papain is the best cell detachment method. Statistical analysis was shown only in the case of a statistical 
difference between methods. 
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The use of flow cytometry is a powerful technique for the analysis of single cells allowing the 
analysis of millions of events each run. Lots of information can be extrapolated from the 
experiments, both morphological and on the fluorescence properties of the cells (for a review Givan 
2011). An important principle of flow cytometry data analysis is to selectively visualize the cells of 
interest using a procedure called gating in which is possible to perform analysis only on a desired 
population excluding the other cells. For the apoptosis assay, we decided to use papain (12U/mL) 
for its lowest background in the control sample. After the optimization of the cell detachment 
method, we performed all the experiments with the different conditions as in the experiment with 
apoptotic nuclei. Cells were treated with dopamine (100µM), dopamine plus the DAT inhibitor 
GBR (100nM), dopamine plus tyrosinase, and dopamine plus tyrosinase in the presence of the DAT 
inhibitor GBR. In the first image (fig.17) is represented the dot-plot of FSC and SSC. This type of 
plot gives information about cell size. It is possible to note that in control sample, cells are mainly 
grouped in the ―healthy‖ population (the red dots in the P1 population). This is because they have 
specific parameters of dimensions. On the other hand, in the different treatments that leads to 
apoptosis, cell shrinkage (a morphological sign of apoptosis) results in a decrease in forward light 
scatter (FSC) and a reduced side scatter (SSC) leading the cells to concentrate in the ―dead‖ 
population (P2). In the second image (fig. 18) is represented the double labeling experiment, in 
which there are four quadrants. The low-left quadrant (Q3) represents cells, which are negative for 
both ANNEXIN-V -FLUOS (marker for apoptotis) and PI (marker for necrosis) and are considered 
healthy. The upper left and the lower-right quadrants are cells that are positive for PI (Q1) and 
annexin (Q4) representing respectively necrotic and apoptotic cells. The upper-right quadrant (Q2) 
comprises cells that are positive both for annexin and PI, representing the late-apoptotic population. 
As demonstrated in the previous experiment on apoptotic nuclei, both dopamine and DAQs leads to 
the externalization of phosphatidil-serine (PS) with no statistical difference on the rate of cell death 
between dopamine and DAQs. Dopamine, as demonstrated previously, needs to enter in cells to 
exert its toxicity, since the treatment with the DAT inhibitor had a rescue effect. DAQs exerted their 
cellular toxicity inducing the externalization of PS, but their toxicity do not dependent on their 
internalization by the action of the DAT, demonstrated by the fact that the inhibition of the DAT did 
not show a protective effect. From the data of FSC and SSC is possible to note that both dopamine 
and its oxidized products leads to changes in morphological parameters, represented by the 
relocation of cells from the healthy population (P1) to the dead one (P2). This data confirmed that 
both dopamine and DAQs are toxic for cells. In the histograms (fig. 19), relative to the shift of the 
fluorescence intensity of the ANNEXIN-V probe, is visible that both dopamine and DAQs leads to 
a reposition of the peak from lower values in the healthy population to higher values in the 
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apoptotic one. The increase in the ANNEXIN-V fluorescence is a parameter that confirm that both 
dopamine and DAQs leads to the externalization of phosphatidil-serines. In the case of pre-
treatment with the DAT inhibitor in addition to dopamine, the percentage of ANNEXIN-V positive 
cells are comparable to the control sample confirming the dopamine DAT-dependent pathway of 
toxicity. In the case of DAQs, the DAT inhibitor did not show a rescue effect suggesting again that 
DAQs are toxic species, but do not depend on DAT internalization activity. With the use of a 
different technique, we can confirm that both dopamine and DAQs are toxic for cells, but dopamine 
needs to enter cells to exert its toxic effect, while DAQs do not. In the third image (fig. 19) is 
represented the peak of fluorescence of the ANNEXIN-V probe. Since in the apoptotic process 
there are two concomitant events: number of cells that undergoes apoptosis and number of 
phosphatidil-serine that are externalized, it is possible to note the shift of the fluorescence of 
annexin and the cell number that exhibit fluorescence. This kind of shift is also visible in the 
fluorescence channel for PI (fig 20) leading to the conclusion that in the toxic affect of dopamine 
and DAQs are implied two different mechanism: apoptosis and necrosis with the first prevalent on 
the latter in terms of percentages. With the data extrapolated from the FACS analysis we plotted the 
percentage of cells that were positive for annexin in the Q4 and Q2 population (positive for annexin 
representing apoptotic cells, and positive for both annexin and PI representing cells that are in late-
apoptosis stage.)  
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Fig. 17. dopamine and DAQs affect cell morphology. Dot-plot of FSC and SSC. Is evident the relocation of cells 
from the population of ―healthy‖ cells (P1 population) to ―dead‖ cells (P2) population. 
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Fig. 18. dopamine and DAQs lead to the externalization of phosphatidil-serine. Dot-plot of double labeling 
experiment.  
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Fig 19. dopamine and DAQs induce a shift in the ANNEXIN-V  signal due to externalization of phosphatidil-serine. 
Histogram of the fluorescence intensity of ANNEXIN-V  probe. 
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Fig. 20. dopamine and DAQs also induce a shift in the PI fluorescence, a marker of necrosis or late apoptosis. 
Histograms of the PI fluorescence shift. 
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Fig. 21. Both dopamine and DAQs leads to the externalization of phosphatidil-serine. Statistical analysis of FACS data, 
represented by the percentage of ANNEXIN-V  positive cells with a statistical difference in respect to the control 
sample. Staurosporine was used as positive control. 
 
With the use of FACS technique, we evaluate one of the first marker of apoptosis: phosphatidil-
serine externalization and we confirmed the previous data obtained from apoptotic nuclei. Both 
dopamine and DAQs led to morphological changes in cells but the pre-treatment with the DAT in 
the case of dopamine led to a rescue effect. On the other hand DAQs and the co-treatment with the 
DAT inhibitor show the same degree of morphological changes. From the double labeling 
experiments is possible to appreciate the rise in the percentage of cells that are both positive for 
ANNEXIN-V  probe and PI indicating a small amount of necrotic signal and a high degree of 
apoptotic signal that is also visible in the fluorescence peak shift for both the probes used. 
 
 
3.3 Mitochondrial superoxide production 
Oxidative stress and mitochondrial dysfunction have been proposed as possible mechanism implied 
in the pathogenesis of Parkinson’s disease. To explain the selective death of dopaminergic neurons, 
dopamine has been proposed to have also toxic properties when not properly stored in synaptic 
vesicles. Chemistry of auto-oxidation and enzyme-mediated oxidation of dopamine leads to the 
production of ROS. The main site of ROS production is the mitochondria where a 1-2% of the 
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molecular oxygen is converted into superoxide anion: the first ROS produced. With the purpose to 
dissect the mechanism of auto-oxidation and enzyme-mediated oxidation of dopamine toxicity, and 
to evaluate if there are differences in this different mechanism to induce cell death, we evaluate the 
production of superoxide anion using a specific probe: MitosoxRed. This probe, specific for 
mitochondrial superoxide anion, is live-cell permeable and it is rapidly and selectively targeted to 
the mitochondria. Once inside the mitochondria, the probe is oxidized by superoxide anion, but no 
other reactive oxygen species, and exhibits red fluorescence. (fig. 22) 
 
 
Fig 22. Oxidation of MitoSOX™ Red indicator to 2-hydroxy-5-(triphenylphosphonium)hexylethidium by superoxide 
(O2 –.)  
 
The experiment was carried out with two different techniques: time-lapse imaging for the 
evaluation of the kinetics of superoxide anion production and with FACS for the quantification of 
the superoxide anion produced. 
3.3.1 Time-lapse imaging 
In the first experiment, we evaluate the production of superoxide anion in cells treated with 
dopamine. The cells were incubated with the probe and then treated with dopamine 100µM for 15 
hour. In the image below (fig. 23) is evident the increasing red fluorescence that demonstrate the 
production of superoxide anion.  
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Fig 23. dopamine (100µM) produces superoxide anion through time. 
 
After demonstrating that dopamine auto oxidation induce the production of mitochondrial 
superoxide anion, we treated cells with the DAT inhibitor GBR 12909 and as expected we saw a 
decrease in the red fluorescence intensity demonstrating again that dopamine needs to enter cells to 
exert it’s toxicity that is mediated by the production of superoxide anion. Afterwards we evaluate 
both the action of DAQs and their co-treatment with GBR for the production of superoxide anion. 
As is possible to see from the time-lapse images (fig. 24), the pre-treatment with the DAT inhibitor 
lowered the signal of mitosox probe confirming that dopamine needs to enter cells to induce the 
production of mitochondrial superoxide anion. On the other hand, the treatment of cells with 
dopamine plus tyrosinase did not lead to an increase in the mitosox fluorescence and also in the 
case of pre-treatment with the DAT inhibitor, therefore with conclude that the tyrosinase-mediated 
oxidation of dopamine did not induce the production of superoxide anion. Antimycin A (Nakayama 
et al., 1956) was used as positive control since it inhibits the complex III of the mitochondrial 
electron transport chain (Alexandre and Lehninger, 1984; Campo et al., 1992; Maguire et al., 1992) 
leading to an increase in superoxide anion production.  
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Fig 24. Only intracellular dopamine induce the production of mitochondrial superoxide anion. Antimycin A was used as 
a positive control since it is a complex III inhibitor. 
Using ImageJ software is possible to quantify the increase of the fluorescence intensity of the probe 
through time.  
The photos of the red channel fluorescence were analyzed from the 15h to evaluate the number of 
fluorescent cells and to perform a densitometric analysis. Using the ImageJ software, each cell that 
exhibit red fluorescence was analyzed to obtain the densitometric value of the fluorescence and the 
media of all values of fluorescence of the cells at a given time point  to calculate obtaining the Y 
value the variation of red fluorescence intensity through time (fig 25). 
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Fig 25. kinetics analysis of superoxide anion production. Photos at 15h were analyzed with imaJ software. Each cells 
was analyzed with the densitometric analysis to obtain the fluorescent intensity value and at every time-point was made 
a madia of the intensity values to obtain the Y value. The high degree of deviation is due to the high variability in the 
number of mitosox positive cells, and the fluorescence intensity of each cells.  
 
As seen from the images of the time-lapse, only cytosolic dopamine was able to produce 
mitochondrial superoxide anion, whereas the other treatments were comparable to the basal level 
observed for the control. Two are the possible interpretation for this data: (i) dopamine-quinones do 
not affect the production of mitochondrial superoxide anion or their concentration in not enough to 
increase its level, or (ii) DAQs produce mitochondrial superoxide anion in low quantity and the 
antioxidant defense of cells are able to cope with this production..  Taking advantage from the 
images of the time-lapse we performed a kinetics analysis of the morphological changes associated 
to cell death under the different conditions. An elongated form characterizes our cells, but upon 
death, they become rounded and they detach from the flask. Analyzing the experiment and counting 
the number of dead cells (the ―rounded‖ ones) is possible to note the different rate of cell death 
under the different treatment conditions. (fig. 26) 
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Fig 26. morphological analysis of cell death kinetics induced by the different treatments. 
 
3.3.2 Flow cytometry 
To confirm and to quantify with a different technique, the production of superoxide anion induced 
by our experimental condition, we performed the same experiment as in the time-lapse imaging 
described above, using flow cytometry. Also in this case, we evaluate which cell detachment 
method was the most suitable to minimize background in the control sample. We used the same 
method used for annexin experiments, confirming the use of papain  as the best method. 
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FIG. 27. Papain preserves the morphological features of healthy cells (in P2 population). 
In figure 27 are represented dot-plots of FSC and SSC of FACS analysis. Since the procedure of 
cell detachment is a fundamental requisite for the preparation of sample for FACS analysis, it is 
important to preserve cell morphological features in control sample to be able to appreciate the 
changes in these parameters upon induction of dead stimuli. As in the case for ANNEXIN-V, 
papain was choose as the proper method since cells retain their morphological features as is 
represented in the P1 population (healthy cells). On the other hand, other methods leads to a high 
degree of cell debris. 
In the figure below (fig. 28) are represented histograms of the fluorescence peak of mitosox probe. 
Again it is important to have the lower background signal, and papain was reconfirmed as the 
proper choice due to its peak position on zero values. 
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FIG. 28. Papain leads to the lower background in control sample. 
 
After the evaluation of cell detachment method, we performed the experiments treating cells under 
different condition. In the first image (fig.29), it’s possible to observe the morphological changes of 
the  cells after the different treatments. Both dopamine and DAQs leads to a relocation of cells from 
the ―healthy population (P1) to the dead one (P2). In the second image (fig. 30), in P3 gate are 
represented cells that exhibit the fluorescence of mitosox, and this population is reported even in the 
third image (fig.31) where it can be appreciate the fluorescence shifts from lower values (associated 
to the absence of superoxide anion production) to higher values. Again this technique confirmed 
that only cytosolic dopamine was responsible for the increasing in mitochondrial superoxide anion 
production represented in the P3 gate in the second figure and in the fluorescence shift of the 
mitosox fluorescence in the third one. Antimycin A was used as a positive control since it is a 
complex III inhibitor leading to the production of superoxide anion. 
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Fig 29. Flow cytometry analysis of mitosox red in cells treated with the different treatments. The dot-plot shows 
changes in cells morphology: P1 population (in red) represents healthy cells while P2 population (in green) represent 
death cells.  
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FIG. 30. Dopamine induces the mitochondrial superoxide production while DAQs do not. In the P3 population are 
represented cells that exhibit the mitosox fluorescence. 
Results 
 
81 
 
 
 
FIG. 31. Dopamine induces the shift of the fluorescence peak of mitosox. In this histograms is possible to note the 
fluorescence peak of mitosox and its shift only in the case of dopamine. 
 
With the use of flow cytometry we confirmed the previous results obtained in the time-lapse 
imaging experiments. Only cytosolic dopamine give rise to the production of mitochondrial 
superoxide anion together with changes in morphological features. On the other hand, DAQs led to 
the changes in morphological parameters, but no production of mitosox fluorescence was detected 
leading to the conclusion that DAQs toxicity do not depend on the production of this ROS specie. 
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3.4 Activation of apoptotic cascade  
 
Apoptosis is a tightly regulated mechanism that can be activated by different stimuli and is 
mediated mainly by two different mechanisms: the extrinsic (death-receptor mediated) and intrinsic 
pathway (mitochondrial pathway) that ultimately converges to apoptosis. From previous data, we 
demonstrated that both dopamine and DAQs leads to the activation of apoptosis with typical 
features of this programmed cell death process such as phosphatidil-serines externalization and 
nuclear fragmentation. The data regarding the role of ROS production led to different results 
between dopamine and DAQs. Dopamine led to the production of mitochondrial superoxide anion 
only in the case of its internalization since DAT inhibitor treatment lowered this production to 
control level. On the other hand, DAQs both in the presence and absence of the DAT inhibitor did 
not lead to the production of superoxide anion. We asked if dopamine and DAQs activate the same 
pathway but in different ways, one superoxide anion-dependent and the other one superoxide anion-
independent, or if they activates different apoptotic ways evaluating other markers for apoptosis. By 
western blot analysis using antibody against caspase 3 and Poly (ADP-ribose) polymerase (PARP) 
we evaluate the apoptotic cascade. 
 
3.4.1 Caspase 3 cleavage 
 
The progression of apoptotis is regulated by different proteins among them caspases have a pivotal 
role. The caspase-cascade is one of the several way by which the apoptotic signal is transduced and 
amplified. Caspases are aspartate-specific cysteine proteases and exist all in a inactivated forms as 
pro-caspases. Upon apoptotic signal, they undergo an internal cleavage (performed by other 
proteins or other caspases) to become activated. Caspase 3 is one of the executioner caspases and its 
activation can be induced by different stimuli that are connected both with the extrinsic or intrinsic 
pathway. Once activated, caspase 3 can activates other caspases or affect other proteins that are 
involved in cell shrinkage, membrane blebbing and DNA rapair (for a review Fan 2005). Upon 
induction of apoptosis, caspases play a important role in triggering and amplifying the death signal. 
Different class of caspases are present in mammals, mainly grouped on the level at which they exert 
their role. Caspase-3 is one of the caspases activated in the execution phase of apoptotic cascade, 
therefore we evaluate its cleavage (and subsequent activation) in our experimental conditions. The 
cells challenged with the different treatments were subjected to SDS-PAGE and probed for an 
antibody against total caspase 3. This antibody recognize both full length and cleaved form of 
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caspase-3. From preliminary data is possible to notice that DAQs led to a high degree of caspase-3 
cleavage and therefore to its activation, while dopamine led only to a slight increase in its 
cleavage.(fig.32)  
 
 
Fig 32 DAQs leads to the cleavage and subsequent activation of caspase 3. Representative image of one of the two 
western blot analysis of lysates of cells treated with the different conditions.  
In the figure below (fig. 33.) is represented the densitometric analysis of the cleaved form of 
caspase-3. Since the experiment was performed only in duplicate (only one data shown), it was not 
possible to perform a statistical analysis, but the data of these experiment led to the same result. 
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Fig. 33. DAQs leads to a high degree of caspase-3 cleavage. Densitometric analysis of two experiments on caspase-3 
cleavage. (N = 2). Values are means of the two experiments. For the lack of further experiments, we were not able to 
perform a statistical analysis. 
 
3.4.2.Poly (ADP) ribose polymerase (PARP) cleavage 
Poly (ADP) ribose polymerase (PARP) is a nuclear protein involved in several cellular processes 
including mainly DNA repair functions. Upon the induction of a stress stimulus, PARP is 
responsible to detect signals of DNA damage and activation of the enzymatic machinery for the 
DNA repair. If the stimulus leads to an extensive DNA damage, cells undergo cell death rather than 
spending energy for repairing internal damage. The inactivation of PARP through its internal 
cleavage is achieved by different inducers among them capsase-3. (For a review see Herceg 2001) 
We previous demonstrate that only DAQs were able to activate caspase 3, so we expect to obtain 
the same results in the cleavage of PARP. Control cells and cells treated with dopamine and DAQs 
(the complete analysis is missing) led to observation of a high degree of PARP cleavage only in the 
case of DAQs (fig 34). Despite the lack of the entire experiment and internal controls, this data 
(performed in triplicate) is in agreement with the data obtained from the western blot analysis of 
cleaved caspase 3 leading to the hypothesis that dopamine and DAQs follow different apoptotic 
pathways. 
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FIG. 34. DAQs leads to an extensive PARP cleavage 
 
In the fig 35. below is reported the densitometric analysis of PARP cleavage. 
 
Fig. 35. Densitometric analysis of PARP cleavage.  
 
3.5 Superoxide dismutase 1 and 2 over expression  
 
Oxidative stress along with mitochondrial dysfunction has been implied in the pathogenesis of 
Parkinson’s disease. This condition is a possible link between sporadic and familial form of the 
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disease being that several genes implicated in the familial forms are linked to the maintenance of 
mitochondria morphology, integrity and function.  The data presented in the previous sections on 
the toxicity exerted by dopamine and its oxidation products (DAQs) revealed that both are cytotoxic 
leading to apoptotic cell death, but only cytosolic dopamine led to the production of mitochondrial 
superoxide anion. In this second part of the project we were interested in evaluating the potential 
protective role of superoxide dismutase 1 and 2. Superoxide dismutases are a class of enzymes that 
are responsible for the dismutation of superoxide anion into molecular oxygen and hydrogen 
peroxide and are referred as the first line of defense against the production of ROS. In mammals, 
different superoxide dismutases have been found, which differ for their metal co-factor and cellular 
localization. Superoxide dismutase 3 is a copper-zinc anzyme (SOD3) and is found in the 
extracellular space, superoxide dismutase 1 as well as SOD3, is a copper-zinc enzyme (SOD1) 
mainly found in the cytosol, while superoxide dismutase 2 is a manganese enzyme (SOD2) that is 
found in the mitochondria. (for a review Abreu 2010). Nowadays there is no genetic mutation on 
the superoxide dismutases genes that has been linked to Parkinson’s disease, but several studies 
implied the role for SOD1 and 2 activities in the progression of the disease. Two different studies 
by the same group, based on proteomic analyses of isolated rat brain mitochondria following 
exposure to DAQs, suggested a direct interaction with SOD2 in brain’s mitochondria. In the first 
one, by using a combination of fluorescent probes directed against cysteine or lysine residues, the 
investigators demonstrated that DA oxidation results in the loss of mitochondrial proteins, among 
which SOD2 (Van Laar 2008). In the second study, SOD2 was identified as one of the proteins 
modified by 14C-DAQs in rat brain mitochondria (Van Laar 2009). From a study of Iglesias-
González  and colleagues it has been demonstrated that pre-treatment with superoxide dismutase 
had a protective effect against 6-OHDA induced cell death (Iglesias-González  et al. 2012). Since 
mitochondria dysfunction and oxidative stress is implied in the pathogenesis of PD and considering 
the importance of SOD1 and SOD2 in protecting cells against superoxide anion production, we 
evaluate the role for this two enzymes in protecting cells against dopamine and DAQs toxicity. For 
this purpose the cDNA of superoxide dismutase 1 and 2 were cloned in vectors carrying a 
fluorescence tag (GFP for SOD1 and RFP for SOD2) to monitor at the single cell level the effect of 
the two proteins over expression. 
 
3.5.1 Cloning of SOD1 and SOD2 
 
The human full length cDNA of superoxide dismutase 1 was a kind gift of Dott. Marco Bisaglia in 
the pOTB7 Vector while the human full-length cDNA of superoxide dismutase 2 of Dott. Elisa 
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Belluzzi in the pCMV-SPORT6 Vector. Since these vectors are not suitable for the expression in 
mammalian cells, the sequence of SOD1 and SOD2 were amplified from the origin vector (fig. 36) 
using two primers carrying the EcoRI and BamHI restriction sites and EcoRI and AgeI restriction 
sites (for SOD1 and SOD2 respectively) and cloned into the pAcGFP1-C2 vector and pDsRed1-
N1vector for SOD1 and SOD2 respectively. (fig. 37 and fig. 38). 
 
 
Fig 36 . Schematic representation of cloning strategies.  
 
The enzymes used to clone the SOD1 figx and SOD2 figx sequence are summarized in the red 
boxes . 
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Fig. 37. pAcGFP1-C2 vector map. In the red boxes are highlighted the restriction sites used to clone the SOD1 
sequence in the destination vector 
 
 
Fig. 38. pDsRed1-N1 vector map. In the red 
boxes are highlighted the restriction sites used 
to clone the SOD2 sequence in the destination 
vector. 
 
 
For the properly folding of SOD1, the fluorescent tag was cloned upstream to the SOD1 sequence. 
For SOD2, the cDNA sequence was cloned at the C-terminal sequence of the fluorescent tag to 
preserve the correct translation of the mitochondrial tergeting sequence of the gene. The sequence 
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of the SOD1 and SOD2 and the correct frame of the protein in respect to the N-terminal GFP tag 
(for SOD1) and the C-terminal RFP tag (for SOD2)  were verified by sequencing at the BMR 
genomics, proving that both proteins were in frame to the respective fluorescent tag.  
 
3.5.2 Transient transfection and cellular localization 
 
Cells were transfected with both the empty vectors and the SODs construct to evaluate the correct 
localization of the two protein inside the cells (fig. 3.9).  
 
 
(fig. 39). Transient transfection of both empty vectors (on the left)m and SODs-fusion proteins (on the right). SOD1-
GFP shared a cytosolic localization, while SOD2-RFP shared a spotted pattern suggesting a precise localization insede 
cells. 
 
SOD1 conjugated to the GFP protein was expected to share a cytosolic localization, while the 
SOD2 fusion protein was expected to localized into mitochondria. From fluorescence microscopy 
experiment, we confirmed that our construct  were in the correct localization. SOD1 localized 
mainly in the cytosol. To address the correct localization of SOD2 into the mitochondria, we 
transfected cells with an ampty vector carrying the sequence of yellow-fluorescent protein targeted 
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to the mitochondria. The correct localization of the SOD2-RFP protein was assessed by confocal 
microscope evaluating the merge of YFP florescence of YFP-construct and the SOD2-RFP vector. 
In the the merge visualized, confirmed us that the protein is correct localized in the mitochondria. 
(fig. 40) 
 
 
Fig. 40. SOD-RFP construct correctly localized into mitochondria. Confocal microscopy images confirm the correct 
localization of the SOD2-RFP fusion protein inside mitochondria. 
 
3.5.3 western blot analysis of SODs over expression 
 
To evaluate the over expression of the two SODs fusion proteins in respect to the transfection 
efficiency and for tubulin, cells transfected with the empty vectors and the SODs vector were 
subjected to SDS-PAGE (fig. 41) and quantified by densitometric analysis (fig 42) 
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Fig. 41. western blot analysis of cell transfected with the pAcGFP vector and the vector carryng the SOD1 sequence (A 
and B respectively) and the pDsRed vector and the vector carrying the SOD2 sequence (C and D respectively). 
 
 
Fig. 42. Densitometric analysis of the over expression of SOD1 (A) and SOD2 (B) in respect to transfection efficiency 
and normalized for tubulin. 
 
Once evaluated the cellular model over expressing the two SODs conjugated with the fluorescence 
tag, we evaluate their role against dopamine and DAQs induced toxicity.  
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3.5.4 SODs effect against dopamine toxicity 
 
Transfected cells were treated with increasing concentration of dopamine (like in the experiment in 
the previous section) and the percentage of apoptotic nuclei was calculated for both SOD1 (fig. 43) 
and SOD2 (fig. 44) 
 
 
Fig. 43.  SOD1 over expression has a rescue effect against dopamine toxicity. Percentage of apoptotic nuclei in cells 
over expressing the empty vector (GFP) and the  SOD1-GFP (SOD1). (N = 3, n.s. = p > 0.05, *** = p < 0.01 
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Fig. 44. SOD2 over expression has a rescue effect against dopamine toxicity. Percentage of apoptotic nuclei in cells 
transfected with the empty vector (RFP) and SOD2-RFP (SOD2). 
As expected, both superoxide dismutases 1 and 2 exert their rescue effect on cell viability by 
lowering the level of superoxide anion induced by dopamine accumulation and blocking the 
activation of apoptotic cascade induce by dopamine auto-oxidation process (since we did not detect 
apoptotic nuclei) with no differences in rescue effect exerted by SOD1 or SOD2.  
3.5.5 SODs effect against dopamine-quinones toxicity 
 
The next experiment was carried out to evaluate the effect of the over expression of SODs in 
protecting cells against DAQs. Cells were tranfected with the empty vectors and the vectors 
carrying the sequence of SOD1 and SOD2 and were treated with increasing concentration of 
dopamine plus tyrosinase. For each condition, apoptotic nuclei were counted and the percentage of 
apoptotic nuclei at the different condition were calculated for SOD1 (fig. 45). and SOD2 (fig.46) 
 
 
Fig. 45. SOD1 has no protective effect against DAQs toxicity. Percentage of apoptotic nuclei in cells over expressing 
the empty vector (GFP) and SOD1.  
 
The same experiment was carried out for SOD2 using the empty vector (RFP) as a negative control. 
(fig. 46) 
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Fig. 46. SOD2 has no protective role against DAQs toxicity. Percentage of apoptotic nuclei in cells transfected with 
the empty vector (RFP) and SOD2-RFP (SOD2). 
 
Previous data demonstrated that tyrosinase-mediated oxidation of dopamine induced toxicity in a 
superoxide-independent manner since there was no production of mitosox fluorescence, however 
there was the induction of cell death by activation of apoptosis. The evaluation of the over 
expression of both superoxide dismutases 1 and 2 did not show a rescue effect as in the case of 
dopamine treatment supporting the different role of superoxide anion production in the auto and 
enzyme-mediated process of dopamine oxidation and subsequent cell toxicity. 
Discussion and conclusions 
 
95 
 
4. Discussion and conclusion 
 
Parkinson’s’ disease is a widespread neurodegenerative disorder that still 
nowadays has no cure. The clinical and pathological hallmarks of the disease are 
related to motor dysfunction and to the selective death of dopaminergic neurons in 
the substantia nigra pars compacta of the midbrain. Less than 5% of the cases are 
linked to mutations in several genes but in the vast majority of PD patients the 
cause is still object of debate. Among the several mechanism that have been 
proposed to be triggers and amplifiers of the disease, mitochondrial dysfunction 
and oxidative stress play an important role (Beal MF. 2007, Schapira 2008). Post 
mortem studies provided evidences of both, decreased mitochondrial complex I 
activity (Schapira et al. 1990, Schapira et al. 1989, Mann et al. 1994) as well as 
the presence of oxidative stress markers (Jenner and Olanow 1996). Although 
mitochondrial dysfunction and oxidative stress have been associated to both the 
beginning and the progression of this disease, these processes cannot explain the 
selective death of the dopaminergic neurons of the substantia nigra pars 
compacta. These neurons are characterized by the production of dopamine whose 
improper oxidation chemistry was proposed to lead to toxic products (Graham et 
al. 1978). Under physiological condition dopamine is produced in the cystosol and 
after synthesis it is stored in the synaptic vesicles by the action of the vesicular 
monoamine transporter 2 (VMAT2) where dopamine is stabilized by the low pH. 
Upon the arrival of an action potential, dopamine is released in the synaptic cleft 
where it can exert its function of neurotransmitter. Afterward it is recycled by the 
action of the dopamine transporter (DAT), which placed on the outer membrane 
transports back dopamine to the cytoplasm. If the amount of cytosolic dopamine 
increases, it is degraded into non-toxic species by the action of monoamine 
oxidase (MAO) and catecol-o-methyl transferase (COMT) or it is sequestered into 
lysosomes to form neuromelanin (NM). If dopamine is not cleared in these 
catabolic pathways, it undergoes a process of autoxidation or enzyme-mediate 
oxidation leading to the production of toxic dopamine-quinones (DAQs) and 
reactive oxygen species (ROS) The former have been demonstrate to interact with 
cysteinyl residues of proteins (Belluzzi 2011, Bisaglia 2007, Girotto 2012, 
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Bisaglia 2010b, LaVoie 2005, Van Laar 2008, Van Laar 2009) and to cause 
toxicity by diminishing or blocking proteins activity (Asunama 2003), the latter 
can damage cellular components such as proteins, lipids and DNA leading 
eventually to cell death (Jenner P. 2007). Several enzymes are good candidates for 
the enzymatic oxidation of dopamine, among them tyrosinase has been implied as 
one of the enzyme responsible for the oxidation of dopamine to DAQs (Miranda 
and Botti 1983; Costa et al. 1992). Several studies demonstrated that DAQs 
production in the tyrosinase-mediated oxidation of dopamine are responsible for 
the cellular toxicity (Stokes 1996, Xu 1998, Greggio et al. 2005) but others 
suggest a protective role for tyrosinase by the induction of the production of 
neuromelanin (Sulzer et al. 2000).  
The aim of this project was to understand the mechanism of cell toxicity induced 
by the auto and the tyrosinase-mediated oxidation of dopamine and to evaluate the 
role for superoxide dismutases 1 and 2 in dopamine and DAQs intoxication in a 
cellular model for PD: SH SY5Y.  
The first part of the project focused on dopamine auto and tyrosinase-mediated 
oxidation and the effect on cell viability. Initially, we carried out an experiment to 
test our cellular model for the presence of all the dopaminergic machinery that 
comprises enzymes responsible for the synthesis, storage,and uptake of dopamine. 
To this purpose RNA was extracted from cells, mRNA was retro transcribed to 
obtain cDNA and the proteins of interest were amplified with specific primers. 
These experiments gave us information regarding only the expression level of the 
mRNA of the proteins involved in the dopamine system, but were sufficient to 
confirm the presence of the dopaminergic markers of interest.  
For the first aim of the project concerning about the toxicity of dopamine and 
DAQs we were interested in revealing which type of cell death mechanism was 
induced. In the literature it has been proposed that dopamine induces cell death by 
activating apoptosis (Ziv et al. 1996, Mochizuki et al 1996, Anglade et al. 1997) 
although there are conflicting results (Kosel et al. 1997, Burke et al. 1998, Burke 
et al. 1998).Using different techniques, we investigated the role of apoptosis in 
cell death induced by dopamine and its oxidation products. Using a DNA binding 
dye and fluorescence microscopy, we checked for one of the later stages of 
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apoptosis: nuclear fragmentation. This kind of experiment permits to evaluate the 
morphology of nuclei, which in control sample are rounded, but in the case of 
induced apoptosis became small and fragmented (apoptotic bodies). The 
physiological concentration of dopamine inside cells is not clearly defined, 
although has been reported to be in the nM range, reaching a mM concentration 
inside the synaptic vesicles. (Eisenhofer et al. 2004, Kopin et al. 1993, Santiago et 
al. 1996, West et al. 2003). These studies suggest that a slight increase in 
intracellular dopamine concentration could have important consequences on cell 
viability. For this reason we decided to treat cells with non-letal concentration of 
dopamine. Cells treated with increasing concentration of dopamine (from 0µM to 
150µM) showed a rise in the percentage of apoptotic nuclei in an overnight 
treatment leading to the conclusion that apoptosis was activated. Cells were 
treated with extracellular dopamine, therefore we asked if its toxicity was 
mediated by its internalization in cells by the action of the dopamine transporter 
(DAT). Cell were pre-treated with the specific DAT inhibitor, GBR 12909, 
leading to a rescue effect against dopamine toxicity. This led us to the conclusion 
that dopamine toxicity depends on its internalization by the activity of DAT. 
Cytosolic dopamine can undergo an auto-oxidation process and one enzyme-
mediated. Several studies implied the role of tyrosinase in the oxidation process of 
dopamine and the presence of the enzyme in substantia nigra. (Stokes 1996, Xu 
1998, Greggio et al. 2005). On these premise, to compare dopamine auto 
oxidation process and its enzymatic oxidation, we investigate the role of 
tyrosinase-mediate oxidation of dopamine to speed up the production of dopamine 
quinones and to assess if there was a different rate of cellular toxicity between 
these species generated by different mechanism. Dopamine auto oxidation and the 
enzyme-mediated process did not show a difference in cellular toxicity. The 
positive control with the treatment of cells only with tyrosinase (when compared 
to dopamine 100µM sample) showed also a toxic effect due to the presence in the 
cell medium of L-tyrosine. Tyrosinase poorly catalyze the hydroxylation of L-
tyrosine to DOPA and after the oxidation to dopaminequinones. Anyway, this 
data did not influenced our results, being the ratio between tyrosinase units and 
dopamine is the same in all the concentration tested, and the increase in dopamine 
concentration led to a consequent increased in percentage of nuclear 
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fragmentation in a linear manner. Since we previously demonstrated that 
dopamine toxicity is mediated by the DAT activity, we asked the same question 
for DAQs . Cell were pre-treated with the DAT inhibitor and then treated with 
dopamine plus tyrosinase. We did not see any difference in the toxicity between 
DAT inhibitor treated and untreated experiments leading to the conclusion that 
DAQs are toxic species but their toxicity do not depends on a DAT mediated 
internalization. In this first part of experiments we confirmed that both dopamine 
and DAQs are toxic species since they induce cell death. To confirm that the 
death pathway activated by dopamine and DAQs was apoptosis, we tested our 
cells for another marker of apoptosis: the externalization of phosphatidil-serines 
(PS). During apoptosis there is the loss of membrane asymmetry and this process 
can be detected using Annexin-V-FLUOS, a Ca
2+
-dependent phospholipid-
binding protein with a high affinity for PS. From flow cytometry experiment we 
confirmed the previous data of nuclei fragmentation. Both dopamine and DAQs 
were toxic for cells, as demonstrated by the increasing percentage of cells positive 
for the annexin-v probe, and confirming the reliance on the internalization process 
mediated by the dopamine transporter only in the case of dopamine treatment. In 
the literature it has been proposed that the oxidation of dopamine contribute to the 
production of reactive oxygen species and mitochondrial dysfunction and 
oxidative stress have been long implicated in Parkinson’s disease. To comprehend 
more deeply the toxicity mechanism induced by dopamine and its oxidation 
products, we estimate the production of mitochondrial superoxide anion (using a 
specific probe: MitosoxRed) in relation to exposure to these stressors. Data from 
time-lapse fluorescence microscopy and flow cytometry demonstrated that only 
the auto oxidation process of dopamine induces the production of this reactive 
oxygen species and, once more, this production depends on the internalization 
process of dopamine. DAQs did not induce the production of mitochondrial 
superoxide anion but in any case, activated apoptosis. This data suggested a 
difference in the induction of apoptosis between DA and Ty generated DAQs, and 
convinced us to investigate if there were different apoptotic pathways activated or 
just a different role of superoxide anion- in induced cell death a different oxidative 
dependence induction. Apoptosis is a very complex and tightly regulated process 
that involves several proteins and interaction, but there are mainly two activation 
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pathways that are responsible for the cell demise. One is the death-receptor 
mediated pathway while the other is the mitochondrial one. We performed 
western blot analysis testing our cells challenged with dopamine and DAQs for 
caspase 3 activation (represented by its internal cleavage) and consequent poly 
(ADP) ribose polymerase inactivation (proved by its cleavage). These two 
proteins can be recruited both in the death-receptor pathway and in the 
mitochondrial one, leading to cell death. Data from preliminary results on the 
cleavage of caspase showed a marked degree of caspase3 cleavage impling its 
activation after treatment of cells with DAQs. On the other hand, dopamine did 
not show suche activation. Other experiment are required to perform a statistical 
analysis. Since poly (ADP) ribose polymerase (PARP) is a target of caspase 3 
activation, we evaluate the cleavage of PARP in consequence of dopamine and 
DAQs treatment. Beside the lack of the complete experiment, from preliminary 
western blot analysis, we found a high degree of PARP cleavage after DAQs 
treatment. Even in this case we have to complete the result to reach a robust 
statistical analysis. This preliminary data highlighted a marked difference in 
dopamine and DAQs mediated toxicity convincing us to proceed in the 
investigation on apoptosis process. We are now trying to update the analysis of 
apoptotic pathway to understand the toxicity mechanism induced by dopamine 
and DAQs following backward the apoptotic cascade to identify any differences 
in proteins and interactions activated by the two oxidation processes and to reveal 
at which level it is possible to block the progression of apoptotic cascade. This 
work could reveal common denominators that could highlights possible targets 
involved in the dopamine and DAQs induction of toxicity and for the design of 
new drugs aim at ameliorate and slow down the progression of this disease. 
The second part of the project was focused on the role of superoxide dismutases 1 
and 2 in protecting cells against dopamine and DAQs toxicity. These two 
enzymes play a crucial role and are referred as the first line of defense against 
reactive oxygen species, because they catalyze the dismutation of superoxide 
anion into molecular oxygen and hydrogen peroxide. Considering the crucial 
functions of these two enzymes and the importance of dopamine oxidation 
chemistry in cell death pathway, we designed a cellular model for the over 
expression of both superoxide dismutase 1 and 2. The full length cDNA of both 
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proteins was cloned in two vectors carrying the sequence of green fluorescence 
proteins (GFP) and red fluorescence protein (RFP) for SOD1 and SOD2 
respectively. For the proper SOD1 folding, the protein was cloned at the C-
terminus of the fluorescent tag. while the SOD2 sequence was cloned at the N-
terminus of the fluorescent tag to preserve the mitochondrial targeting sequence. 
Both SOD1 and SOD2 were first tested for their correct localization inside cells. 
SOD1 shared mainly a cytosolic localization, while SOD2 mitochondrial 
localization was tested in a co-transfection experiment with another fluorescent 
protein (mito-YFP) targeted to the mitochondria. The co localization of the latter 
two proteins was assessed by confocal microscopy. Once demonstrated that our 
proteins were correctly localized inside cells, we evaluate their level of over 
expression in comparison with the endogenous ones. For SOD1 we reached about 
eleven fold of over expression with respect to the endogenous one, while for 
SOD2 it was about twofold. To test the effect of both SOD1 and SOD2 in 
dopamine induced cell death, we transfected cells both with empty vectors (as 
negative control) and the SODs vectors. We treated cells with increasing 
concentration of dopamine and the nuclear fragmentation was evaluated with 
fluorescence microscopy experiments. We previous demonstrated that dopamine 
causes an increase in mitochondrial superoxide anion, and we expected to find a 
protective role. Indeed, the experimental data demonstrated that over expression 
of both SOD1 and SOD2 had a rescue effect against dopamine induced cell death, 
lowering the production of superoxide anion. In the same way, we tested SODs 
effectiveness in protecting cells against DAQs induced toxicity. From this data we 
confirmed the superoxide anion-independent toxicity for DAQs, since the over 
expression both of SOD1 and SOD2 did not rescued cells. These data reported a 
different potential for superoxide dismutases against dopamine and DAQs toxicity 
confirming the reliance on superoxide anion production for the former but not in 
the case of latter. Further experiments are necessary to ameliorate the knowledge 
on dopamine toxicity and the differences of the auto oxidation and enzyme-
mediated process. The cell model used has the characteristic features of a high 
DAT and a low VMAT2 activity that permits to easily obtain an increase in the 
cytosolic dopamine concentration providing a useful model to study the toxicity 
of exogenous compounds that are used for PD research (Alberio, Bossi et al 2010, 
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Alberio, Colapinto et al. 2010). The more prominent result of this research is the 
great importance of a proper storage or catabolism of dopamine since a slight 
increase in cytosolic dopamine led to the activation of apoptotic cascade and the 
role for dopamine transporter in mediating extracellular dopamine toxicity. Both 
auto oxidation and enzyme-mediated processes involved in the dopamine 
chemistry are toxic for cells and a more comprehensive knowledge on these 
processes could help to find new strategies to counteract the beginning and the 
progression of the pathology both detoxifying ROS produced by dopamine and 
DAQs, and blocking the apoptotic cascade activated by these two different 
processes. 
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